Expect the unexpected: More clots in kids

BY MICHELE G. SULLIVAN
IMNG Medical News

LAKE BUENA VISTA, FLA. – Venous thromboembolism is “not that uncommon in children” and seems to be on the rise, Dr. James Callahan said at a meeting sponsored by the American College of Emergency Physicians and the American Academy of Pediatrics.

In the general pediatric population, annual incidence is around 1 per 100,000. In hospitalized children, the number is much higher – up to 57 per 100,000. Rates of pulmonary embolism and deep vein thrombosis have increased markedly over the past decade, said Dr. Callahan of the Children’s Hospital of Philadelphia.

“National hospital discharge data show that the disorders increased by about 70% from 2001 to 2007, and other studies show similar increases in other countries,” he noted.

Although no one really knows the reason behind this increase, it’s probably linked to better medical care.

See VTE • page 10

Cortisol breakdown impaired during critical illness

Hydrocortisone ‘stress doses’ overly high

BY MARY ANN MOON
IMNG Medical News

The breakdown and clearance of cortisol are impaired during critical illness, which may account in part for the abnormally high blood levels of cortisol often observed in ICU patients, according to a report in the New England Journal of Medicine.

Hypercortisolemia often accompanies critical illness, but until now it usually has been attributed to increased cortisol production driven by stress-induced activation of the hypothalamic-pituitary-adrenal axis. However, some researchers posit that another possible contributor to hypercortisolemia in this setting might be suppression of the removal of cortisol.

“We hypothesized that cortisol metabolism is reduced during critical illness, contributing to sustained hypercortisolemia with enhanced negative-feedback inhibition of corticotropin,” said Dr. Eva Boonen of the clinical division and laboratory of intensive care medicine, Catholic University of Leuven (Belgium), and her associates.

To test their hypothesis, the investigators studied 158 consecutive adults treated for critical illness in a single hospital in Belgium.

See Cortisol • page 5

Specialists get room in medical home

BY MARY ELLEN SCHNEIDER
IMNG Medical News

The National Committee for Quality Assurance has launched a new program to recognize the role of specialists in the patient-centered medical home.

The program, which launched this spring, evaluates how well specialists do in ensuring access, communication, and care coordination for their patients. The Patient-Centered Specialty Practice Recognition program is based on the concept of the medical home “neighbor” – first developed by the American College of Physicians – and follows the same model as the NCQA’s patient-centered medical home recognition program for primary care physicians.

Most patients see multi-
Significant progress has been made in PAH treatment over the past 2 decades, yet patient morbidity and mortality remain high. There is limited information on the long-term effects of PAH-specific therapies, and many patients continue to experience death, hospitalizations, and the need for additional therapies.

Now is the time for a new perspective in PAH. Experts are calling for future PAH studies to deliver data on the long-term effect of therapy on clinical outcomes, such as hospitalizations and mortality. Actelion is committed to investigating this evolving perspective in PAH.
Survival observed over periods from 1981-1988 and 1982-2006, respectively.
Amiodarone increases cancer risk in men

BY BIANCA NOGRADY
IMNG Medical News

The antiarrhythmic drug amiodarone is associated with an increased risk of cancer, but the effect is significant only in men or at higher doses, according to a Taiwanese population-based cohort study published in Cancer.

“We found that there was a borderline significantly increased risk of cancer among patients who received amiodarone compared with the general population,” wrote Dr. Vincent Yi-Fong Su of the Taipei (Taiwan) Veterans General Hospital and his colleagues. Patients either of male sex or with more than 180 cumulative defined daily doses within the first year “had a significantly higher risk of developing cancer, and those with both factors had an even greater SIR [standardized incidence ratio] of 1.46 (P = .008).”

While all patients receiving amiodarone had a slight increase in their overall risk of cancer (SIR, 1.12; 95% CI, 0.99-1.26; P = .067), the risk was significantly higher in men (SIR, 1.18; 95% CI, 1.02-1.36; P = .022) but not in women (SIR, 0.99; 95% CI, 0.79-1.23).

“One possible explanation for this difference is that there is a 37% higher clearance rate of amiodarone in females than in males because of differences in cytochrome P450 3A4 activity and the percentage of body fat,” the authors reported.

The study also found a dose-dependent relationship between amiodarone and cancer risk. Among patients in the middle and top tertile of cumulative defined daily dose, the adjusted hazard ratios were 1.70 (95% CI, 1.02-2.84; P = .042) and 1.98 (95% CI, 1.22-3.22; P = .006) respectively, after adjustment for age, sex, and comorbidities.

The researchers examined data from 6,418 patients treated with amiodarone, 43% of whom were female, using information from the Taiwan National Health Insurance Research Database. During the median 2.6-year follow-up, 280 patients developed cancer, with no significant differences found in the type or location of cancer. Amiodarone, approved by the Food and Drug Administration in 1985, is a fat-soluble drug with a long elimination half-life, so large amounts of the drug can build up in the soft tissues after prolonged treatment, and postmarketing surveillance had suggested an increased risk of lung masses, thyroid cancer, and skin cancer.

The researchers noted an increase in the incidence of cancer in the first year after amiodarone therapy (SIR, 1.32; 95% CI, 1.05-1.64; P = .002), although they suggested this may be due to surveillance bias (Cancer April 8, 2013 [doi.wiley.com/10.1002/cncr.27881]).

“To provide an initial, thorough evaluation of the etiology of arrhythmias and to monitor the toxicity of amiodarone in follow-up studies, an increased number of medical examinations are performed in patients treated with amiodarone,” the authors wrote. “Thus, the cancer incidence within the first year falsely increases due to early detection.”

While the study excluded patients with preexisting malignancies, researchers could not account for other risk factors, such as obesity, smoking and alcohol use, environmental exposure, and family history of cancer.

The authors concluded that while extensive screening for occult cancers in patients taking amiodarone was not practical, they advocated closer surveillance of cancer events in future amiodarone trials.

The study was partly supported by the Taipei Veterans General Hospital. The authors reported no relevant financial conflicts.

CHEST Physicis Is Online
CHEST Physician is available on the Web at chestnet.org/ chestphysician.

CHEST PHYSICIAN
CHEST Physician, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to the members of the American College of Chest Physicians. Content for CHEST Physician is provided by International Medical News Group, a Frontline Medical Communications Inc. company. Content for NEWS FROM THE COLLEGE is provided by the American College of Chest Physicians.

The statements and opinions expressed in CHEST Physician do not necessarily reflect those of the American College of Chest Physicians, or its officers, regents, members, and employees, or those of the Publisher, The American College of Chest Physicians, its officers, regents, members, and employees, and Frontline Medical Communications Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

POSTMARKER: Send change of address (with old mailing label) to CHEST Physician, Subscription Service, 151 Fairchild Ave., Suite 2, Plainview, NY 11803-1709.

CHEST PHYSICIAN (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Frontline Medical Communications Inc., 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Subscription price is $230.00 per year. Phone 973-206-3434, fax 973-206-9378. EDITION: OFFICE 5635 Fisher Lane, Suite 6100, Rockville, MD 20852, 240-221-4500, fax 240-221-2548

©Copyright 2013, by the American College of Chest Physicians

IMNG SOCIETY PARTNERSHIPS, A DIVISION OF IMNG MEDICAL MEDIA
President and CEO, IMNG Medical Media Alan J. Imhoff
Director, IMNG Society Partnerships Mark Branca
Editor in Chief Mary Jo M. Dales
Executive Editors Denise Fulton, Kathy Scarpone
Managing Editor Lori Buckner Farmer
Executive Director, Operations Jun Chiong
Director, Print Production Judi Shetter
Creative Director Louise A. Koenig
Display Advertising Managers Derek Lundsten, 973-713-2650, dlundsten@americanmedicalcomm.com, Lauren Provenzano, 609-306-5776, lprovenzano@americanmedicalcomm.com
Subscriptions Jessica Post 973-206-3234, fax 973-206-9378, jpost@frontlinemedcom.com
Advertising Sales 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609 973-206-3434, fax 973-206-9378
Classified Sales Representative John Baltazar 917-488-1528, jbaltazar@americanmedicalcomm.com

F RONTLINE MEDICAL COMMUNICATIONS
Chairman Stephen Stoneburner CFO Douglas E. Grose
President, Custom Solutions John H. Wahl, 973-206-8989
wah@frontlinemedcom.com
Vice President, Custom Programs Carol Nathan, 973-206-8099
cnathan@frontlinemedcom.com
Corporate Director, Marketing and Research Lori Raskin 973-206-8013
lraskin@frontlinemedcom.com
Cortisol breakdown lags in ICU

ICU and 64 demographically matched but not critically ill control subjects. They measured five aspects of cortisol metabolism: daily corticotropin and cortisol levels, plasma cortisol levels reflecting the clearance, metabolism, and production of cortisol during an infusion of deuterium-labeled tracers; plasma clearance of a therapeutic 100-mg IV bolus of hydrocortisone; urinary levels of cortisol metabolites; and levels of major cortisol metabolizing enzymes in liver and adipose tissue.

Their findings demonstrated that elevated cortisol levels in critically ill patients were only partially explained by an increase of 83% in cortisol production, as compared with controls.” In addition, impaired breakdown and clearance of cortisol contributed to hypercortisolism, the investigators reported. They found a reduction of more than 50% in cortisol clearance after administration of the 100 mg of hydrocortisone (N. Engl. J. Med. 2013 March 19 [doi: 10.1056/NEJMoa1214969]).

The clinical implications of these study findings markedly change our understanding of the stress response. Reduced inactivation of cortisol may be important not only to increase circulating levels but also to potentiate cortisol levels and activity within the vital tissues that express inactivating enzymes.

“More pragmatically, the data suggest that ‘stress doses’ of hydrocortisone, which are advocated to replace cortisol production in critically ill patients who are presumed to have adrenal failure, are at least 3 times too high,” researchers said.

The data also suggest that “a low cortisol response to corticotropin stimulation does not necessarily reflect adrenal failure, since cortisol production in critically ill patients is not subnormal, and the suppressed clearance maintains hypercortisolism. Our results may therefore help to explain why studies investigating the effect of the daily administration of 200 mg of hydrocortisone in patients with sepsis ... have had conflicting results,” they added.

This study was supported by the Belgian Fund for Scientific Research, the British Heart Foundation, the Flemish government, and the European Research Council. No relevant conflicts of interest were reported.

Why wait?

Start SPIRIVA at COPD diagnosis

The only long-acting anticholinergic bronchodilator indicated to reduce exacerbations

- Lowest branded co-pay for 96% of patients covered by commercial and Medicare plans
- The #1-prescribed branded COPD maintenance medication
- Prescribed for over 6 million US COPD patients since 2004

Important Safety Information

Spiriva® HandiHaler® (tiotropium bromide inhalation powder) is contraindicated in patients with a history of hypersensitivity to tiotropium, ipratropium (atropine derivatives), or any components of SPIRIVA capsules.

SPIRIVA HandiHaler is not indicated for the initial treatment of acute episodes of bronchospasm, i.e., rescue therapy.

Immediate hypersensitivity reactions, including urticaria, angioedema (swelling of lips, tongue or throat), rash, bronchospasm, anaphylaxis, or itching may occur after administration of SPIRIVA. Additionally, inhaled medicines, including SPIRIVA, may cause paradoxical bronchospasm. If any of these occurs, treatment with SPIRIVA should be stopped and other treatments considered.

Use with caution in patients with severe hypersensitivity to milk proteins.

SPIRIVA HandiHaler should be used with caution in patients with narrow-angle glaucoma or urinary retention. Prescribers should instruct patients to consult a physician immediately should any signs or symptoms of narrow-angle glaucoma, or prostatic hyperplasia or bladder-neck obstruction occur.

SPIRIVA may interact additively with concomitantly used anticholinergic medications. Avoid coadministration with other anticholinergic-containing drugs.

The most common adverse reactions in the 1-year placebo-controlled trials were dry mouth, upper respiratory tract infection, sinusitis, pharyngitis, non-specific chest pain, and urinary tract infection. In addition, the most commonly reported adverse reactions from the 4-year trial not included above were headache, constipation, depression, insomnia, and arthralgia.

Indication

SPIRIVA HandiHaler is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and for reducing COPD exacerbations.

Please see accompanying Brief Summary of full Prescribing Information.

Visit SPIRIVA.com to find out how SPIRIVA can help your COPD patients breathe better

References:
1. SPIRIVA Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2013.
2. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.

SPIRIVA was developed by Boehringer Ingelheim and is being co-promoted by Boehringer Ingelheim and Pfizer. Copyright ©2013, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
For hypertension, pair CPAP with weight loss

BY SHERRY BOSCHERT
IMAG Medical News

SAN FRANCISCO – A 24-week program combining weight-loss efforts with continuous positive airway pressure production yielded greater reductions in systolic blood pressure in obese patients with obstructive sleep apnea, compared with either intervention alone, in a study of 187 participants.

In an intent-to-treat analysis of three groups reduced systolic pressures to a statistically similar extent, compared with baseline — decreases of approximately 8 mm Hg in the combination group and 4 mm Hg in the with either monotherapy. Among 136 patients who adhered to therapy by completing the trial, however, systolic blood pressure decreased by a mean of 14 mm Hg in the 62 patients randomized to weight-loss efforts alone and 3 mm Hg in 58 patients who got CPAP alone.

A 14 mm Hg drop in systolic blood pressure is an "important reduction" with potentially significant clinical benefits in obese patients with obstructive sleep apnea, Dr. Julio A. Chirinos said at the annual meeting of the American College of Cardiology.

Previous observational studies have shown strong links in obesity, obstructive sleep apnea, and hypertension but have not been able to prove any incremental blood pressure benefit to combining treatments for obesity and sleep apnea. Dr. Chirinos and his associates conducted an ancillary analysis of data from the Cardiovascular Consequences of Obstructive Sleep Apnea trial, which focused primarily on the treatments' effects on C-reactive protein levels. The study randomized adults with at least moderate obesity and moderate to severe obstructive sleep apnea and C-reactive protein levels greater than 8 mg/L to the combination of CPAP and weight-loss efforts compared with each intervention alone.

"For hypertension, pair CPAP with weight loss."

Main Objective: To compare the addition of continuous positive airway pressure (CPAP) to weight loss with weight loss alone in moderately obese patients with obstructive sleep apnea (OSA).

Key Findings: The combination of CPAP and weight loss led to greater reductions in systolic blood pressure (SBP) compared with weight loss alone.

Study Details: A 24-week trial randomized 187 moderately obese patients (BMI ≥30 kg/m²) with OSA to either continuous positive airway pressure (CPAP) and dietary modification, dietary modification alone, or usual care (control) groups.

Results:
- The combination group (CPAP + weight loss) had greater reductions in SBP compared with weight loss alone (−8.0 mm Hg vs. −4.0 mm Hg).
- The weight loss group had greater reductions in SBP compared with control (−4.0 mm Hg vs. −1.0 mm Hg).

Conclusion: The combination of CPAP and weight loss is more effective than either intervention alone in reducing systolic blood pressure in moderately obese patients with OSA.

Systolic blood pressure fell 14 mm Hg in patients receiving the combination of weight-loss efforts and CPAP.

DR. CHIRINOS

"For hypertension, pair CPAP with weight loss."

Main Objective: To compare the addition of continuous positive airway pressure (CPAP) to weight loss with weight loss alone in moderately obese patients with obstructive sleep apnea (OSA).

Key Findings: The combination of CPAP and weight loss led to greater reductions in systolic blood pressure (SBP) compared with weight loss alone.

Study Details: A 24-week trial randomized 187 moderately obese patients (BMI ≥30 kg/m²) with OSA to either continuous positive airway pressure (CPAP) and dietary modification, dietary modification alone, or usual care (control) groups.

Results:
- The combination group (CPAP + weight loss) had greater reductions in SBP compared with weight loss alone (−8.0 mm Hg vs. −4.0 mm Hg).
- The weight loss group had greater reductions in SBP compared with control (−4.0 mm Hg vs. −1.0 mm Hg).

Conclusion: The combination of CPAP and weight loss is more effective than either intervention alone in reducing systolic blood pressure in moderately obese patients with OSA.

Systolic blood pressure fell 14 mm Hg in patients receiving the combination of weight-loss efforts and CPAP.

DR. CHIRINOS

"For hypertension, pair CPAP with weight loss."

Main Objective: To compare the addition of continuous positive airway pressure (CPAP) to weight loss with weight loss alone in moderately obese patients with obstructive sleep apnea (OSA).

Key Findings: The combination of CPAP and weight loss led to greater reductions in systolic blood pressure (SBP) compared with weight loss alone.

Study Details: A 24-week trial randomized 187 moderately obese patients (BMI ≥30 kg/m²) with OSA to either continuous positive airway pressure (CPAP) and dietary modification, dietary modification alone, or usual care (control) groups.

Results:
- The combination group (CPAP + weight loss) had greater reductions in SBP compared with weight loss alone (−8.0 mm Hg vs. −4.0 mm Hg).
- The weight loss group had greater reductions in SBP compared with control (−4.0 mm Hg vs. −1.0 mm Hg).

Conclusion: The combination of CPAP and weight loss is more effective than either intervention alone in reducing systolic blood pressure in moderately obese patients with OSA.

Systolic blood pressure fell 14 mm Hg in patients receiving the combination of weight-loss efforts and CPAP.

DR. CHIRINOS

"For hypertension, pair CPAP with weight loss."

Main Objective: To compare the addition of continuous positive airway pressure (CPAP) to weight loss with weight loss alone in moderately obese patients with obstructive sleep apnea (OSA).

Key Findings: The combination of CPAP and weight loss led to greater reductions in systolic blood pressure (SBP) compared with weight loss alone.

Study Details: A 24-week trial randomized 187 moderately obese patients (BMI ≥30 kg/m²) with OSA to either continuous positive airway pressure (CPAP) and dietary modification, dietary modification alone, or usual care (control) groups.

Results:
- The combination group (CPAP + weight loss) had greater reductions in SBP compared with weight loss alone (−8.0 mm Hg vs. −4.0 mm Hg).
- The weight loss group had greater reductions in SBP compared with control (−4.0 mm Hg vs. −1.0 mm Hg).

Conclusion: The combination of CPAP and weight loss is more effective than either intervention alone in reducing systolic blood pressure in moderately obese patients with OSA.

Systolic blood pressure fell 14 mm Hg in patients receiving the combination of weight-loss efforts and CPAP.
Continued from previous page

1 mg/L to the three intervention groups. Baseline characteristics were similar among groups. Approximately 41% of patients were hypertensive at baseline.

In the per-protocol analysis of patients who adhered to therapy, the decreases in systolic blood pressure, compared with baseline, were statistically significant in the combination and weight-loss groups but not the CPAP group, reported Dr. Chirinos of the University of Pennsylvania, Philadelphia.

Body weight and body mass index decreased significantly in the weight-loss and combination groups, compared with baseline, but did not change significantly in the CPAP group. Patients in the weight-loss and combination groups dropped approximately 7 kg in the intent-to-treat analysis and 10-11 kg in the per-protocol analysis. BMI decreased by a mean of two to three points in the intent-to-treat analysis and by approximately four points among those who adhered to therapy. No specific details were provided about the weight-loss efforts.

Mean arterial pressure decreased significantly in all three groups, compared with baseline, in both intent-to-treat and per-protocol analyses, but fell significantly more in the combination group, compared with monotherapy, in the per-protocol analysis. Among patients adherent to treatment, mean arterial pressure decreased by more than 10 mm Hg in the combination group, compared with approximately 4 mm Hg decreases in the CPAP and weight-loss groups but not the CPAP group.

Only combination therapy significantly reduced brachial pulse pressure, compared with baseline (by approximately 3 mm Hg), in the intent-to-treat analysis.

Mean arterial pressure decreased significantly in all three groups, compared with baseline, in both intent-to-treat and per-protocol analyses, but fell significantly more in the combination group, compared with monotherapy, in the per-protocol analysis. Among patients adherent to treatment, mean arterial pressure decreased by more than 10 mm Hg in the per-protocol analysis. In the per-protocol analysis, brachial pulse pressure dropped significantly, compared with baseline, in the combination group (a 6 mm Hg decrease) and the weight-loss group (a 4 mm Hg decrease) but not in the CPAP group.

Brachial pulse pressure decreased significantly with combination therapy in the intent-to-treat analysis but not with either treatment alone. Mean brachial pulse pressure in the per-protocol analysis decreased significantly with combination therapy (a 6-mm Hg reduction) or weight-loss therapy (a 4-mm Hg decrease), but increased in the CPAP group.

Carotid-radial pulse pressure amplification measurements did not change significantly from baseline in any group.

The findings are limited by the study’s strict criteria for patient inclusion, its lack of arterial blood pressure monitoring, the use of noninvasive estimates of central pressure measurements, and its short duration. The study used carotid tonometry to measure central pulse pressure.

The study excluded patients with blood pressures greater than 160/95 mm Hg, those with predominantly central sleep apnea, patients using supplemental oxygen, and anyone in a high-risk occupation or with a record of dangerous driving. Also among the excluded were patients with confounders of systemic inflammation, sustained arrhythmia, unstable cardiopulmonary disease, severe restless leg syndrome or chronic pain causing frequent night awakenings, pregnancy, severe depression, or serious medical or psychological conditions that might compromise their safety in the study, and prior CPAP within 8 weeks of the study.

The American Heart Association funded Dr. Chirinos’s analysis. Dr. Chirinos reported having no financial disclosures. Some of his associates reported financial relationships with multiple pharmaceutical companies.

**VIEW ON THE NEWS**

*Dr. Vera De Palo, FCCP, comments: There can be many contributing factors to hypertension: genetics, lifestyle, diet, medications, and other co-morbidities. The potential multifactorial etiology of a patient’s hypertension may allow practitioners to plan a multipronged strategy for treatment and control. Addressing all the variables that are in the control of the physician and the patient may offer the greatest improvement.*

---

**ACCP Simulation Program for Advanced Clinical Education**

**Upcoming Summer Courses**

**MECHANICAL VENTILATION**

- Essentials of Mechanical Ventilation for Providers
  - July 25, Northbrook, IL
  - Gain a solid foundation of basic critical care ventilation skills for managing the critically ill, and take away practical solutions for issues faced by patients in respiratory failure.

- Mechanical Ventilation: Advanced Critical Care Management
  - July 26-28, Northbrook, IL
  - Attend this comprehensive, interactive program to study advanced techniques and practice skills for managing the critically ill patient.

**BRONCHOSCOPY**

- Essentials of Bronchoscopy
  - August 1-2, Northbrook, IL
  - Review the fundamental areas of bronchoscopy, including sedation, sampling techniques, difficult cases, and management of complications.

- Endobronchial Ultrasound (EBUS)
  - August 4-5, Northbrook, IL
  - Study fundamental knowledge needed to learn endobronchial ultrasound (EBUS), such as the basics of ultrasound, mediastinal anatomy, and lung cancer staging guidelines.

**CRITICAL CARE**

- Achieving Optimal Outcomes in the ICU: Knowledge, Skills, and Behaviors
  - August 15-16, Northbrook, IL
  - Discuss current challenges experienced in critical care management. Practice simulated critical care scenarios, and learn how to integrate these applications within your own institutional workflows.

---

**Board Review On Demand**

Review presentation and learning materials from the 2012 board review courses. Purchase 1-year access to mp4 audio/video files from the board courses to:

- Review board review content anytime.
- Use course pretests and posttests to test your knowledge.

**On demand materials are available for:**

- ACCP Pulmonary Medicine Board Review 2012
- ACCP Critical Care Medicine Board Review 2012
- ACCP Pediatric Pulmonary Medicine Board Review 2012

---

**Simulation Education, Real Results.**

Purchase Your Access Today boardreview.chestnet.org

Link to board review on demand products from the bottom of the home page.
Only 11% of health plan payments are value based

WASHINGTON – Only about 11% of health plan payments to physicians and hospitals are tied to performance or efficiency – meaning that almost 90% of payments are still fee for service, according to a report released by Catalyst for Payment Reform.

The San Francisco–based nonprofit is a collaborative of employers and health plans that advocates the overhaul of the nation’s health care payment infrastructure by encouraging more value-based payment.

Using data provided by commercial health plans, the group determined that 11% of hospital pay-ments, 6% of outpatient specialist payments, and 6% of primary care physician payments are “value oriented.”

Of those payment arrangements, 57% involve provider risk such as bundled payment, capitation, and shared-risk payment. The remaining 43% provide incentives, such as shared savings or pay for performance.

The main goal of Catalyst for Payment Reform (CPR) is to raise the volume of value-based commercial payments to health care providers to 20% by 2020. Coalition members said that they saw reason for both pessimism and optimism in the report’s findings.

“Obviously, these results are pretty disappointing,” said Dr. Robert Galvin, chief executive officer of Equity Healthcare, which buys health care coverage, “but we have to be realistic about where we are right now and how fast change is happening.”

Susan Delbanco, executive director of CPR, noted that in 2010, 1%-3% of provider payments were tied to performance. Given the latest information, “it looks to me like we’re on a fast track and that we may get there before 2020,” she said.

The group’s research also found that about 2% of health plan enrollees are enrolled in an accountable care organization or a patient-centered medical home.

Most health plan payments (about 75%) are still made to specialists, while 25% go to primary care physicians, according to the analysis. Non-fee-for-service payments are still not entirely rewarding or providing incentives to improve the quality of care. Only 35% of those value-based payments have quality of care as a factor.

Dr. Richard Gilfillan, director of the Center for Medicare and Medicaid Innovation at the Centers for Medicare and Medicaid Services, said that the agency was “thrilled” with the report, noting that it showed that private payers were helping encourage a transformation in payment.

“We’re not discouraged – we think that change is happening, it’s underway,” Dr. Gilfillan said at the press briefing.

The growing number of physicians participating in new payment models reflects a cultural shift, said Dr. Mark Smith, president and chief executive officer of the California HealthCare Foundation. “I think we have turned the corner on providers recognizing the feasibility, the desirability, and in fact, the inevitability of the kinds of payment reforms that you’ve heard about.”

The California HealthCare Foundation and the Commonwealth Fund provided the funding for the National Scorecard on Payment Reform, and a sister effort, the National Compendium on Payment Reform.

The scorecard tabulated data that 57 health plans provided to the National Business Coalition on Health. Participation is voluntary, and not all 57 plans answered all questions posed. The plans represent 104 million people in the commercial group market, or about two-thirds of the total commercially insured population in the United States.

Respondents were primarily large health plans, which means the results may not necessarily reflect the entire group market.

Medical home makes room (and rules) for specialists

Medical home makes room (and rules) for specialists

NCQA from page 1

Medical home makes room (and rules) for specialists

Dr. Burt Lesnick, FCCP, comments: The medical neighbor model appears to be a good concept. It will be interesting to see what hurdles will be necessary for accreditation and if payers will reimburse providers who make the effort to document this level of service.

Medical home makes room (and rules) for specialists

Dr. Burt Lesnick, FCCP, comments: Pay for quality is a trend in commercial insurance payments. It is not yet clear what will be the tipping point at which practices change how they deliver services. Of course, the big question is how Medicare might be restructured.
NEW!

Power to Stay Active and Sleep Well

- 4.83 lbs. total weight
- Up to 15 hours of battery life*
- 24/7 capable therapy
- 1-3 LPMeq capable
- No tanks or carts required
- FAA-approved
- 4-way carrying case
  (backpack, shoulder strap, waist pack & briefcase)

*At 1 LPMeq with 3-hour external battery not included in Standard Package.

1.800.220.0977
www.InovaLabs.com

Follow Us @InovaLifeChoice

Manufactured & Distributed by InovaLabs
3500 Comsouth Dr, Ste 100, Austin, TX 78744
Clots are a growing culprit in children

VTE from page 1

for children with chronic illness. “As we keep children with more and more complex diseases alive longer and longer, we’re going to keep seeing this trend,” he said.

VTEs can be harder to recognize in children than in adults. The symptoms can be subtle and non-specific. When signs and symptoms do occur, Dr. Callahan said, “we

CT angiography is probably the most reliable diagnostic tool. The scan is quick, which is good, but the child has to be immobilized and you need at least a 22G intravenous cannula and may need a 20G.’

may not have PEs and DVTs high on the list of possibilities for children, so we can miss them. Sometimes it takes a while to figure it out. In autopsy studies, up to 4% of children showed signs of a pulmonary embolism or DVT. Only half of them had any symptoms at all, and a DVT was suspected in only about 15%.”

Risk peaks at two times during a child’s life: in babies younger than 1 year and in older teens. In infants, the incidence is often linked to prematurity and the need for an indwelling catheter. The second peak is in teens around 15-18 years old who don’t have any underlying illness. These cases account for about 50% of childhood DVTs. In older children, the pathophysiology is similar to what’s seen in adults – they have some circulatory stasis, get a clot, and it breaks off.

A minority of children who develop a DVT or PE have some chronic predisposing illness – often a thomboembolism, but renal disease, systemic lupus erythematosus, and even some medications also can be underlying culprits. The indwelling line remains the single biggest risk factor for children of all ages.

What to look for

Pleuritic chest pain, the most common symptom, is present in up to 84% of cases. The incidence of dyspnea, at 58%, is much lower than in adult patients. About half of children with a VTE will cough, and about a third show hemoptysis. Children are likely to be hypoxicemic and tachypneic, run a fever, and have abnormal breath sounds and increased second heart sound.

Hypoxemia can be a very telltale sign. “If I see that in a child in the absence of pneumonia, I start to get worried. If I see an adolescent who presents with unexplained pleuritic chest pain, dyspnea, hypoxemia, and one risk or more of the risk factors, I go looking for it,” Dr. Callahan said.

The Wells criteria – a classic risk stratification system for adults – just don’t work in children. “Even if you change the numbers to make it age specific, it’s not really helpful,” he said.

Situs tachycardia is the most reliable cardiac sign for pulmonary embolism in a child, but the ECG is completely normal in up to 23%. D-dimer levels are helpful in adults but have never been validated in children. A ventilation/perfusion scan is useful in otherwise healthy children, but “many of these kids have underlying disease, and that can make it inaccurate,” he pointed out.

CT angiography is probably the most reliable diagnostic tool. “The scan is quick, which is good, but the child has to be immobilized and you need at least a 22G intravenous cannula and may need a 20G,” Dr. Callahan said.

Treatment options

The treatment approach for children is also different than it is for adults, Dr. Callahan said.

“There are no good studies on thrombolysis for children, but in certain cases – such as a massive PE with hemodynamic instability – it can be considered.”

There are strict contraindications, however, including major surgery needed within 7-10 days; active bleeding; surgery on the central nervous system; ischemia, trauma, or hemorrhage within the past 30 days; recent seizures; a low platelet count and fibrinogen level; and uncontrolled hypertension.

Tissue plasminogen activator has not been well studied in pediatric populations and isn’t indicated for use in children, but it is often used off label. Low-molecular-weight heparin has become the treatment of choice for most. Its longer half-life and more predictable response make it a good choice for children, who will also need less frequent monitoring.

“Neither low-molecular-weight nor unfractionated heparin should ever be used in children with heparin-induced thrombocytopenia,” Dr. Callahan said. “In this setting, one of the newer anticoagulants, such as direct thrombin or selective Xa inhibitors, should be used.”

About 10% of children with a clot will die, but mortality is highly associated with underlying disease. Children who do survive have a risk of recurrence and an increased risk of death with each recurrence.

Dr. Callahan reported having no financial conflicts of interest.
Genetics factor into adolescent, adult smoking habits

BY HEATHER LINDSEY
IMNG Medical News

Genetic risk may contribute to the rapid progression of daily and heavy smoking during adolescence and subsequent problems with nicotine dependence and smoking cessation in adulthood, according to a recent study.

The research may have implications for the development of initiatives that deter smoking in adolescents, reported Daniel W. Belsky, Ph.D., of the University of North Carolina at Chapel Hill and Duke University Medical Center, Durham, N.C., and his associates in JAMA Psychiatry. The 38-year longitudinal study included 1,037 men and women from the Dunedin Multidisciplinary Health and Development Study of New Zealand. Researchers assessed participants with a multilocus genetic risk score (GRS), originating from three meta-analyses of genome-wide association studies (GWAS) that used the number of cigarettes smoked daily as their phenotype. Dr. Belsky and his team focused their investigation on the single-nucleotide polymorphisms in 15q23.1 and 19q13.2 (JAMA Psychiatry 2013 March 27 [doi:10.1001/jamapsychiatry.2013.736]).

Genotyping was possible in 880 Dunedin subjects. In addition to evaluating family history in these individuals, researchers gathered smoking information at eight assessments from age 11 years to age 38 years. The GRS was not associated with whether or when subjects started smoking. “In fact, daily smokers who did not progress to heavy use were at lower genetic risk than individuals who never smoked,” researchers wrote.

Among 627 ever-smokers in the cohort, those with a higher genetic risk were more likely to rapidly progress to heavy smoking, meaning 20 or more cigarettes daily (hazard ratio, 1.35; 95% confidence interval, 1.14-1.58).

Adolescents with high genetic risk had a greater chance of becoming daily smokers by age 15 (relative risk, 1.24; 95% CI, 1.06-1.45) and progressing to heavy smoking by age 18 (RR, 1.43; 95% CI, 1.10-1.86).

Over the course of the study, subjects with a high genetic risk accumulated more pack-years of smoking. As adults, 27% of ever-smokers became nicotine dependent and those at higher genetic risk had a greater chance of doing so (HR, 1.27; 95% CI, 1.09-1.47). Additionally, of 277 cohort members who smoked daily during their 30s, those with a higher genetic risk were more likely to use smoking to cope with stress.

Further analyses found that smoking cessation was also difficult in adults at high genetic risk. For example, in the cohort of 277 daily smokers, 53% quit smoking a month or longer across 72-months’ follow-up; however, relapse occurred in 62%. Quitters with a higher genetic risk had a greater chance of relapsing (HR, 1.22; 95% CI, 1.02-1.45). Only 20% of daily smokers abstained from smoking for a year or more.

Associations detected between the GRS and smoking phenotypes were small, noted the study authors. “Children who our study would classify at high genetic risk are not guaranteed to become addicted if they try smoking, and, even more importantly, children we would classify at low genetic risk are not immune to addiction.”

Finally, researchers found that the GRS score did not correlate with family history. “The GRS contained different information about risk for developmental and mature phenotypes of smoking behavior, compared with family history,” investigators reported.

The authors said that their research “adds a genetic dimension to long-standing arguments” in favor of early cigarette prevention of cigarette consumption, including surtaxes and age restrictions on tobacco purchases.

Tailored online feedback is asthma tool

BY SHERRY BOSCHERT
IMNG Medical News

SAN FRANCISCO – A website designed to give people with asthma tailored feedback about whether they need to see a doctor and what questions to ask when they do may have helped improve asthma control in a randomized, controlled trial.

The study randomized patients to get access to one of two modules in a “patient activation website.” The asthma module provided tailored feedback about patients’ asthma control, helped them decide whether they needed to visit a medical provider sooner than already scheduled, and suggested questions for patients to ask their providers. The control group got access to a module that suggested questions they should ask their primary care providers about preventive services such as cancer screening.

Among 325 adults who completed 12 months of follow-up (157 in the intervention group and 168 in the control group), measures of asthma control improved significantly in both groups, with most measures improving significantly more in the intervention group vs. the control group.

Mean scores on the Asthma Control Test (ACT) increased from 17.7 at baseline to 19.9 at 12 months in the intervention group and from 17.9 to 19.1 in the control group, both of which were significant improvements. The greater improvement in the intervention group was statistically significant compared with the control group, Jennifer M. Pogar and her associates reported in a poster presentation at the annual meeting of the Society of Behavioral Medicine.

The proportion of patients with controlled asthma (defined as an ACT score of 20 or greater) increased from 50% at baseline to 73% at 12 months in the intervention group, and from 53% to 67% in the control group, both of which were statistically significant improvements. The difference between groups, however, did not reach statistical significance, reported Ms. Pogar, a researcher at Pennsylvania State University, Hershey, Pa.

The mean number of inhaled asthma medications being used increased by 0.4 in the intervention group between baseline and the 12-month follow-up, compared with 0.2 more medications in the control group, a statistically significant difference.

The results suggest that websites that provide tailored feedback to patients with chronic conditions such as asthma may help them control their diseases, Ms. Pogar said.

The investigators’ financial disclosures were not available.

Providers order fewer tests when fees are listed

BY JANE ANDERSON
IMNG Medical News

Providers order slightly fewer laboratory tests when given test fee information at the time of ordering, and adopting this tactic on a widespread basis might help reduce the number of inappropriately ordered diagnostic tests, a study from Johns Hopkins University, Baltimore, found.

The researchers compared ordering behavior among all providers in Johns Hopkins’ computerized system during both a baseline period and an intervention period, when fees were shown for some tests. Orders fell 9.1% for the tests that had fee data shown, and the number of tests per patient-day decreased, too.

Meanwhile, orders for tests that did not have fee data shown increased. Overall, the hospital saved $400,000 in lab charges during the 6-month intervention period when test fee data were displayed, the study said.

Dr. Vera DePal, FCCP, comments: Care providers strive for engagement by the patient in managing their own health care. This model promises improved control and engagement. As the population of health care consumers becomes more comfortable with online activities, a greater segment of patients may become more active managers of their health, resulting in a healthier population overall.
NHANES follow-up captures asthma/allergy mortality

BY SHARON WORCESTER
IMNG Medical News

SAN ANTONIO — A diagnosis of asthma, allergic disease, or obstructive or restrictive lung disease among participants in the first National Health and Nutrition Examination Survey conferred a significantly increased long-term risk of death due to respiratory causes – as did a diagnosis of asthma in the older group, Dr. Jessica R. Savage reported in a poster at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.

"This association was not likely explained by underlying bronchitis or an increased risk of death due to respiratory infection but was likely due to asthma itself," said Dr. Savage of Brigham and Women’s Hospital, Boston.

"I think the main conclusions are reassuring – no increase in mortality if you are young and have allergies. Some studies show an association between allergy and stroke/heart disease. We were worried that with the rising increase in allergy, there would also be an increase in these other diseases. But we did not see that, fortunately.

"We saw an association with asthma and respiratory death even in the young. Of course, one always needs to remember to be vigilant with asthmatics, but overall for young people the news is good," she said during an interview.

Data were obtained from the National Health and Nutrition Examination Survey (NHANES I), which was conducted from 1971 to 1975 and included 31,937 adults. Of these participants, 14,407 were included in the NHANES I Epidemiologic Follow-Up Study (NHEFS) and were assessed for doctor-diagnosed asthma, allergic rhinitis, food allergy, and urticaria.

Asthma and allergic diseases, which typically manifest in childhood, have increased in the United States over the last 3 decades.

A subcohort of 6,913 subjects received a more detailed health interview and examination, including prebronchodilator spirometry and percent predicted forced expiratory volume and forced vital capacity. Vital status and cause of death were obtained in 2006.

After adjustment for age, gender, income, education, race, and smoking history, a sensitivity analysis for the association between asthma and mortality demonstrated a significantly increased long-term risk of death in those who were aged 40-75 years at baseline (hazard ratio, 1.22), but not for those aged 25-39 years at baseline (HR, 1.20).

The hazard ratios for all-cause mortality in these groups, after exclusion of subjects with bronchitis, were not statistically significant (1.16 and 1.52, respectively).

Hazard ratios for the association between asthma and respiratory mortality were significant for the older and younger groups, respectively. The hazard ratios for these groups remained statistically significant at 8.36 and 1.82, respectively, after exclusion of subjects with bronchitis.

This study also demonstrated that older subjects with obstructive lung disease were at significantly increased risk of both all-cause and respiratory mortality and that older subjects with restrictive lung disease were at significantly increased risk of both all-cause and cardiovascular mortality.

Conversely, older adults with urticaria had a reduced risk of cardiovascular mortality.

Cancer-related mortality was slightly, but not significantly increased in the younger subjects diagnosed with urticaria, and in the older subjects diagnosed with asthma or moderate-to-severe lung obstruction.

"Asthma and allergic diseases, which typically manifest in childhood, have increased in the United States over the last 3 decades. Asthma and allergy may increase mortality by directly reducing lung function or may be markers of immune dysregulation that could lead to systemic inflammation," Dr. Savage noted.

Although prior studies have demonstrated associations between allergic sensitization and stroke, hives and cancer, asthma and mortality, and obstructive lung disease and cardiovascular events, the effects of asthma and allergic disease on long-term, mortality have been unclear, Dr. Savage added.

"The findings (of this follow-up study) provide some insight regarding the effects of asthma and allergic disease on long-term mortality," Dr. Savage said.

The NHEFS is a joint project of the National Center for Health Statistics and the National Institute on Aging in collaboration with other agencies of the U.S. Public Health Service.
Assisted-suicide program delicately meets needs

BY MARY ANN MOON
IMNG Medical News

The Death with Dignity program, a pioneering program that includes medically assisted suicide for competent, terminally ill adults treated at a comprehensive cancer center in Seattle, has been well accepted by patients, families, and clinicians, according to a report published online in the New England Journal of Medicine.

The report details the experience in 2009-2011 with the Death with Dignity program at the Seattle Cancer Care Alliance, which serves all of the Pacific Northwest. The program, “designed to adhere to legal regulations, maintain safety, and ensure the quality of patient care,” allows patients with a life expectancy of 6 months or less because of a diagnosed medical condition (usually cancer) to request and self-administer lethal medication prescribed by a physician.

This experience may help to inform efforts to introduce similar programs in other states. At present, Hawaii, Pennsylvania, and Vermont are all considering pertinent legislation, said Dr. Elizabeth Trice Loggers of the Fred Hutchinson Cancer Research Center, Seattle, and her associates.

The program’s policy – written by the Seattle Cancer Care Alliance’s medical director and approved by a majority of the medical executive committee members, as with any clinical policy – requires that patients request information about medically assisted suicide from their physicians, or that these clinicians raise the topic, to be considered for referral. Participation is entirely voluntary for medical staff and faculty members. Every patient who is a potential participant is first assigned an advocate, a licensed social worker employed by the Alliance, who assists patients, family members, pharmacists, and physicians throughout a multistep process of participating.

To determine epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement status in the diagnosis of advanced non-small cell lung cancer (NSCLC),

OBTAIN ADEQUATE TISSUE SAMPLES IN NSCLC FOR BIOMARKER TESTING

...and ensure that EGFR mutation and ALK rearrangement status are available to inform treatment decisions

Help improve patient outcomes through a multidisciplinary approach to biomarker testing
• Biomarker testing at diagnosis is critical to providing timely information that drives clinical decisions
• Obtain adequate quantity and quality of tissue samples to help ensure an accurate diagnosis and reduce the need for repeat biopsies

Visit LETSTESTNOW.COM to learn more

Find current information on biomarker testing and treatment decisions in advanced NSCLC
Watch expert videos and thought leader commentary, including sample requirements for biomarker testing
Review innovative techniques on streamlining biomarker testing and implementing a multidisciplinary approach
Access interactive tools and patient education resources

Dr. Paul A. Selecky, FCCP, comments: Physician-assisted suicide (PAS) is legal in only a small number of patients, although this may increase in time. This article describes a well-organized and seemingly thorough process to assist patients who might consider such a death. Although 97% of patients identified loss of autonomy as the reason for requesting, only 21% chose PAS. Their assurance of preserving autonomy may have satisfied the remaining patients.
**What’s in a name? Is ‘palliative care’ too loaded?**

*BY PATRICE WENDLING  IMNG Medical News*

NEW ORLEANS—That which we call a rose by any other name would smell as sweet. Perhaps not, if the true topic is palliative care.

A telephone survey of 169 patients with advanced cancer found that those randomized to hear the term “supportive care” instead of “palliative care” rated their understanding, overall impressions, and future perceived need for those services significantly higher. In contrast, there was no significant difference in outcomes when patients heard either a “patient-centered” or “traditional” description of palliative/supportive care services, Rachael Maciaz said at the annual meeting of the American Association of Hospice and Palliative Medicine.

“It may be that ‘palliative care’ is so loaded...because of family members’ or friends’ experiences with this in the past that [they think] their family member is going to die,” she said. “Perhaps what comes after, no matter how you describe it, you can’t change that impression.”

Patients with stage IV solid tumors or refractory/recurrent hematologic malignancies were recruited from 20 oncologists at two comprehensive cancer centers in Pittsburgh, and randomized to one of four survey groups: “palliative care/patient-centered,” “palliative care/traditional,” “supportive care/patient-centered,” and “supportive care/traditional.”

Outcomes were measured using 10-point Likert scales, with zero meaning “do not understand at all,” or impression “not favorable at all” or “strongly disagree with” a need for services.

The majority (63%) of patients were female, 95% were white, 88% were Catholic/Christian, 4% Jewish, and 7% other religion or agnostic. The most common cancer diagnoses were breast (32%), lung (18%), and gastrointestinal (13%). Their average age was 62, and roughly 11% had prior exposure to palliative care services.

The supportive care groups had significantly higher mean ratings than did the palliative care groups for overall understanding of what the service had to offer (7.7 vs. 6.8) and for overall favorable impressions (8.4 vs. 7.3), said Ms. Maciaz, a fourth-year medical student and a Doris Duke Clinical Research Fellow at the University of Pittsburgh. Patients rated their current need for supportive and palliative care services equally, but were more likely to perceive a future need for supportive services for themselves or family (8.6 vs. 7.7).

The qualitative results paralleled the quantitative results.

“I had the impression that fewer patients went in with an impression of palliative care and that if you could explain it in ways that made perfect sense and described how awesome it is, that it wouldn’t matter if it was [called] palliative or supportive,” Ms. Maciaz said.

No matter how you describe it, when people hear “palliative care,” they think their family member is going to die, said researcher Rachael Maciaz.

---

**Dr. Paul A. Selecky, FCCP, comments:** Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.

---

**VIEW ON THE NEWS**

Dr. Paul A. Selecky, FCCP, comments: Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.

---

**Continued from previous page**

potential participants are aware of alternatives to medically assisted suicide, such as palliative care and hospice care. The patient’s terminal status is verified, and if the attending physician doesn’t wish to participate, a prescribing physician and a consulting physician are chosen from a group of willing providers.

Psychosocial and psychological assessments are required to ensure the patient’s competence to make the choice of assisted suicide and to identify any depression, which would make the patient ineligible to participate. The patient’s preferences for interventions and health-care directives are documented. Grief support, legacy support, and bereavement support are offered through periodic calls and visits.

The patient and his or her family meet with the prescribing clinician and the consulting clinician to review the diagnosis, prognosis, treatment alternatives, and end-of-life issues. After a mandatory waiting period of 15 days, a written prescription is then sent to the pharmacy, and the pharmacist schedules another appointment with the patient and family to discuss preparation of the drug(s), potential side effects, and the concomitant use of prescription antiemetics.

Patients are then free to fill the prescription or not and to take the drug(s) or not, as they wish. To date, 114 patients have inquired about the Death with Dignity program, and 44 (38%) either did not pursue the matter further or were deemed ineligible to participate.

Thirty patients (26%) have made a first oral request to initiate the process but either decided not to participate or died before completing the process. Forty patients (35% of those who made an initial inquiry) received prescriptions for lethal medication, and all 40 have died. Twenty-four chose to die by ingesting the medication (secobarbital).

Thus, only 21% of the participants actually used assisted suicide. Death with Dignity participants accounted for 2.4% of all annual deaths among patients at the Seattle Cancer Center Alliance.

The reasons patients gave most often for participating in the assisted-suicide program were loss of autonomy (97%), inability to engage in enjoyable activities (89%), and loss of dignity (75%).

“We have not received any complaints from family members or caregivers regarding our process or the manner of death. Anecdotally, families describe the death as peaceful (even when death has taken longer than the average of approximately 35 minutes),” Dr. Loggers and her associates wrote (N. Engl. J. Med. 2013;368:1417-24 [doi:10.1056/NEJMsa1213398]).

“Both patients and families frequently express gratitude after the patient receives the prescription, regardless of whether it is ever filled or ingested, typically referencing an important sense of control in an uncertain situation,” they noted.

Opponents of medically assisted suicide have argued that legislation would disproportionately affect vulnerable populations, such as racial or ethnic minorities, low-income groups, or cognitively impaired patients. The Death with Dignity experience refutes this argument, as most participants were white, male, and well educated, the investigators said.

There have been no unexpected complications among patients who chose assisted suicide, but one patient remained alive for a day after taking the medication. This protracted dying process caused distress to both the family members and the clinicians involved. Similar cases have been reported previously, they added.

---

**VIEW ON THE NEWS**

Dr. Paul A. Selecky, FCCP, comments: Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.

---

Dr. Paul A. Selecky, FCCP, comments: Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.

---

Dr. Paul A. Selecky, FCCP, comments: Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.

---

Dr. Paul A. Selecky, FCCP, comments: Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.

---

Dr. Paul A. Selecky, FCCP, comments: Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.

---

Dr. Paul A. Selecky, FCCP, comments: Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.

---

Dr. Paul A. Selecky, FCCP, comments: Use of the term “palliative care” has been an ongoing problem of misunderstanding for years, not only for patients, but for their physicians as well. Too many associate palliative care directly with the act of dying, which is only one aspect of the spectrum of what is included in the application of palliative care.

The focus is to treat the patient’s suffering of whatever cause (physical, emotional, spiritual, psychosocial), often well in advance of the dying process. Either term (supportive or palliative) needs to be well-defined and publicized.
25 YEARS MAKES US
ALPHA-1 EXPERTS
OUR COMMITMENT MAKES US PROLASTIN® C
ALPHA₁ - PROTEINASE INHIBITOR (HUMAN)

Our commitment extends beyond PROLASTIN®-C (Alpha₁-Proteinase Inhibitor [Human]), the #1 prescribed augmentation therapy for alpha₁-antitrypsin deficiency.¹ There’s also PROLASTIN DIRECT®, a comprehensive patient support program that provides access to alpha₁-pharmacy, a dedicated alpha₁-pharmacy, and a national network of alpha₁-certified infusion nurses. PROLASTIN DIRECT offers the only alpha₁-disease management program with proven patient outcomes²—and it’s the only place to order PROLASTIN-C.

For more information, call 1-800-305-7881 or visit www.prolastin.com.

IMPORTANT SAFETY INFORMATION
PROLASTIN-C, Alpha₁-Proteinase Inhibitor (Human) is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to deficiency of alpha₁-proteinase inhibitor (alpha₁-antitrypsin deficiency). The effect of augmentation therapy with any alpha₁-proteinase inhibitor (alpha₁-PI) on pulmonary exacerbations and on the progression of emphysema in alpha₁-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials. PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha₁-PI deficiency has not been established.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. PROLASTIN-C is contraindicated in patients with antibodies against IgA.

The most common drug related adverse reactions during clinical trials in ≥1% of subjects were chills, malaise, headache, rash, hot flush, and pruritus. The most serious adverse reaction observed during clinical studies with PROLASTIN-C was an abdominal and extremity rash in one subject.

PROLASTIN-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see brief summary of PROLASTIN-C full Prescribing Information on adjacent page.


© 2013 Grifols Inc. All rights reserved. February 2013 PR33-0313
PROLASTIN®-C
Alpha_1-Proteinase Inhibitor
(Human)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PROLASTIN®-C (Alpha_1-Proteinase Inhibitor [Human]) safely and effectively. See full prescribing information for PROLASTIN-C.

PROLASTIN®-C (Alpha_1-Proteinase Inhibitor [Human]) Lyophilized Preparation

For Intravenous Use Only

Initial U.S. Approval: 1987

----------INDICATIONS AND USAGE----------

PROLASTIN-C is an alpha_1-proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to deficiency of alpha_1-proteinase inhibitor (alpha_1-antitrypsin deficiency). The effect of augmentation therapy with any alpha_1-proteinase inhibitor (Alpha_1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha_1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials. PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe Alpha_1-PI deficiency has not been established.

----------CONTRAINDICATIONS----------

IgA deficient patients with antibodies against IgA.

----------WARNINGS AND PRECAUTIONS----------

- IgA deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions.
- This product is made from human plasma and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease agent.

----------ADVERSE REACTIONS----------

The most common drug related adverse reactions during clinical trials in ≥ 1% of subjects were chills, malaise, headache, rash, hot flush, and pruritus.

To report SUSPECTED ADVERSE REACTIONS, contact Grifols Therapeutics Inc. at 1-800-520-2807 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

----------USE IN SPECIFIC POPULATIONS----------

- Pregnancy: No human or animal data. Use only if clearly needed.

GRIFOLS
Grifols Therapeutics Inc.
Research Triangle Park, NC 27709 USA
U.S. License No. 1871
08941114-BS
Revised: June 2012
Sleep Strategies: Is a cry in the dark best for childhood insomnia?

No area of pediatric sleep medicine stirs more controversy in the mainstream media than the treatment of behavioral insomnia of childhood (BIC), defined in the International Classification of Sleep Disorders (American Academy of Sleep Medicine [AASM], 2005) as difficulty falling and/or staying asleep that is behavioral in etiology and not explained by a medical or psychiatric cause.

The diagnosis, which is usually made via a caretaker report, is divided into three subtypes: limit-setting type (ie, bedtime problems), sleep onset association type (night-wakers), and a combined type. Including all three subtypes, disease prevalence is estimated at 20% to 30% in infants, toddlers, and preschoolers (Morganthaler et al. Sleep. 2006;29(10):1277). Though the disease has been associated with dural behavioral problems, it also has significant adverse effects on the parents, including sleep deprivation, maternal depression, and increased parental stress (Wake et al. Pediatrics. 2006;117[3]:836). Unfortunately, an astounding 84% of children with sleep disturbances continue to have them at 3-year follow-up, with persistent sleep fragmentation noted in as many as 18% of school-age children (Kataria et al. J Pediatr. 1987;110[4]:642; Sadeh et al. Dev Psychol. 2000;36[3]:291).

Treatment options

One likely contributor to the endurance of BIC into later childhood is the uncertainty about the optimal method of treatment. According to the AASM’s behavioral practice parameters for bedtime problems and night-waking in infants and children, the standard of care is to use the behavioral strategy of unmodified extinction, more commonly known as the ‘cry-it-out’ method. This technique involves putting the child to bed at a designated time and not responding to the child’s protests/cries until it is time to wake him up in the morning, unless there are significant safety or illness concerns.

Another practice standard is to use unmodified extinction, allowing a parent to remain in the room without reacting to the child (“extinction with parental presence”); a gentler method called “graduated extinction” or “modified extinction” allows the parent to briefly remain with the child at predetermined times but with progressively longer intervals until sleep is achieved. The idea behind each of these methods is to allow the child to develop self-soothing skills so that he or she is able to fall asleep independent of parental intervention. By not providing the positive reinforcement of parental attention, the undesired behavior (crying or screaming) is extinguished.

Although a number of studies support the efficacy of these behavioral interventions in significantly reducing bedtime resistance and night-wakings (Mindel et al. Sleep. 2006;29(10):1263), controversy understandably exists about the morality of allowing a child to cry for extended periods of time without consolation. Proponents of attachment parenting dub unmodified extinction as cruel and unusual punishment. The debate lies in whether withholding a parent’s response to a child’s cries at night results in long-term damage.

Of children with sleep disturbances, 84% continue to have them at 3-year follow-up. This study was an extension of the previously published Infant Sleep Study, a randomized controlled trial evaluating the shorter-term effects of a behavioral sleep intervention on infants who were identified by mothers as having sleep problems at 8 months of age (Hiscock et al. Arch Dis Child. 2007;92[11]:952).

Two techniques were used in this study: “controlled comforting” (graduated extinction) and “crying out.” This latter technique, also known as “extinction with parental presence,” with the parent gradually distancing himself or herself from the child. Price and colleagues followed up on those children at 6 years of age, analyzing differences in intervention vs control groups based upon parental reports and standardized questionnaires of emotional and behavioral problems, perception of sleep as a problem, clinical sleep problems, psychosocial health-related quality of life, and stress, as measured by morning cortisol levels. Additionally, researchers assessed the child-parent relationship; parenting styles; and evaluated maternal depression, anxiety, and stress. Results showed no statistically significant difference between the intervention and control groups in any of the measured outcomes, supporting the theory that behavioral sleep interventions have no long-term adverse effects on children.

Prevention strategies

Regardless of whether or not extinction methods are benign or harmful to an infant, there are parents who simply prefer noncrying methods for getting their child to sleep. In addition to extinction, the AASM practice parameters also propose parent education/prevention as a standard recommendation. This intervention focuses on preventing sleep problems by teaching parents to establish good sleep routines within their child’s first 6 months of life.

Strategies typically include developing consistent sleep schedules and providing an appropriate level of parental interaction during sleep initiation and nighttime awakenings. By checking on the infant to bed in a “drowsy but awake” state can foster development of self-soothing and sleep initiation skills. Outside of these standard recommendations, two guideline recommendations are “delayed bedtime with removal from bed/positive bedtime routines” and “scheduled awakenings.”

The first refers to the technique of temporarily delaying the child’s bedtime in order to increase the likelihood of the child falling asleep in the bed by increasing sleep pressure. Optionally, the child may be removed from the bed if he or she is unable to achieve sleep within a predetermined time period. Implementation of scheduled awakenings requires that parents be familiar with their child’s night waking patterns; based upon this schedule, the child is preemptively woken up 15 to 30 minutes prior to the expected spontaneous awakening and consoled in a typical manner. Gradually, these scheduled awakenings are faded out, with the intention of increasing consolidated sleep. There was insufficient evidence for the task force committee to support any one technique or combination of techniques over another.

Beyond BIC

Despite the emotional wear that extinction therapy for BIC can have on a parent, the lack of direct data suggesting harm makes it reasonable to include as a recommendation to frustrated caregivers. It is critical to be aware that underlying medical issues, which may be contributing to nighttime awakenings (eg, gastroesophageal reflux, pain due to acute illness such as hand-foot-and-mouth disease, and upper respiratory infection) must be ruled out before a behavioral sleep problem is diagnosed and treated in this fashion.

Most importantly, both providers and parents should be aware that extinction methods are not the only behavioral methods available to manage BIC. Further studies to demonstrate the efficacy of these other methods in larger populations or to develop additional methods need to be conducted, hopefully leading to an expansion of the practitioner’s toolbox for treating BIC. When a family presents for management of an infant with behavioral insomnia, the provider should practice the art of tailoring a treatment plan that considers parent and child temperament, schedules, and social and cultural perspectives to optimize success while minimizing parental stress.

Sophia Kim, MD
 Fellow, Sleep Medicine
 and
 Roberta Leu, MD
 Director, Pediatric Sleep Disorders Program
 Emory University School of Medicine
 Atlanta, Georgia
I am now past the midpoint of my term as ACCP President and wanted to share with you some of the ‘work’ that has been on my desk. This doesn’t represent all that is happening at the College (… there are other stacks and stacks of those files on my desk), but these activities have lately been active in the middle of my desk.

Before I speak to these issues, I did want to share with you my “Post Midterm Presidency Mood” — it is very upbeat! This is a great organization to work with and for, and the dedication and commitment I feel in working with our skilled staff and volunteer leadership makes it even better. I [we] still have got a lot of work to do before CHEST 2013, but this has been a wonderful opportunity and personally most fulfilling. But enough about me!

So what is on Darcy’s desk?

Strategic planning
An effective organization must have goals—boring but important, ambitious and exciting, and every kind of goal in between. These goals must be regularly established and agreed upon, and the progress of the organization periodically assessed and judged against these same goals. This is an exercise many organizations speak about (and perhaps hold the occasional strategic planning session), but few undertake with genuine passion, and even fewer critically judge their performance and activities.

The ACCP is presently critically assessing its performance and activities. The ACCP is viewed as the premier organization delivering the very best possible clinical education for our members and our professions, and it is essential for us to regularly review/revise/update our strategic goals and direction.

Traditionally we’ve compiled 1-year goals/strategies/tactics, but we are now looking farther into the future with longer-term goals and direction. The process started in earnest this January and most recently involved the participation of more than 200 individuals this spring. You could sense the excitement and enthusiasm for what we are doing, and the desire to do even more, and better. Currently, the Board of Regents and College staff are carefully reviewing and refining the information garnered to date and will continue to work on this important task this spring and summer, and into the fall.

We are not in a rush — this is far too important a process to rush — but we will be sharing much more with you as the outcomes of this important and intensive process become available.

Leadership development
We have also been further augmenting our efforts in leadership development. As you may know, we held a bigger and more intensive Leadership Summit this past March for current ACCP leadership at the annual Spring Leadership Meeting, which included various keynote and breakout sessions targeted at different levels of experience within the organization. But that was just a few days in the year, and we know that the needs for leadership in health care exist every day of the year.

We are currently targeting more intensive activities to those members who have previously attended our past leadership development courses, in order to build on the substantive skills and understanding they have garnered to date. In addition, we are presently soliciting current/past ACCP senior leaders to serve as mentors and will be rolling out a more formal mentorship program this summer.

Work is also underway on a leadership development certificate program, which would give successful participants an ACCP Certificate of Completion for specific leadership development courses/curricula. And finally, we are markedly augmenting this important initiative and theme at CHEST 2013 in Chicago, with “Brown Bag” lunch sessions, which will address various leadership topics in a very welcoming atmosphere.

Who can say no to a free lunch? Of course, our very successful Leadership Development Course will once again be held at CHEST 2013, targeting participation from those within 5 years of finishing their fellowship—the call for nominations for the course will be sent out in the next few weeks.

Organization leadership
But leadership goes well beyond just individuals, and it is important for the ACCP to also enable and practice inspiring organization leadership. Our patients and their families, our members and colleagues in various clinical professions, and health-care systems are looking for that exact type of leadership—trusted, responsible, and innovative. With that in mind, the ACCP has had the honor of serving as Chair of the Forum of International Respiratory Societies (FIRS) this year. Born in 2001, FIRS is composed of the leading international respiratory societies in the world (American College of Chest Physicians [ACCP], American Thoracic Society [ATS], Asian Pacific Society of Respiriology [APSR], Asociación Latinoamericana de Tórax [ALAT], European Respiratory Society [ERS], International Union Against Tuberculosis and Lung Disease [IUATLD], and the Pan African Thoracic Society [PATS]); with observer participation by the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD).

FIRS represents over 70,000 professionals worldwide, who devote their working lives to various aspects of respiratory health or disease.

Recently, FIRS has been developing... Continued on following page

‘Beyond Our Walls’: New ACCP headquarters taking shape

Construction of the ACCP’s headquarters is in full swing for the new Glenview, Illinois, ACCP campus. With the foundation laid out and framing starting to go up, the inspired plans for the ACCP offices and Innovation and Simulation Center are becoming concrete (and steel).

“It’s very exciting to see the plans literally taking shape,” says ACCP President Dr. Darcey Marciniuk, FCCP. “What is being built is much more than just a building. It’s a campus, which will allow us to bring cutting-edge education and innovative technologies together with the great minds of the ACCP, all for the betterment of patient care.”

ACCP members and campaign supporters can witness the evolution of the campus themselves with a virtual visit to the “Beyond Our Walls: Advancing the Future of Chest Medicine” website (beyondourwalls.chestnet.org). There, visitors can watch a live video feed of real-time construction taking place at the building site and view aerial and ground photographs that uniquely capture initial phases of development.

Visitors to the “Beyond our Walls” site can also take a three-dimensional animated tour of the campus, hear donor testimonials, and make a financial commitment in support of the building project.

There are many ways to express support of the campaign in a lasting, memorable way. A number of prime naming opportunities are still available for those ACCP members interested in a legacy gift that exemplifies their commitment to advancing chest medicine and the health of their patients. Whether a donation is a combined group gift for the naming of an interior innovation space or a personal commitment showcased on an exterior sidewalk paver, financial support at any level is vital.

“We recognize that ACCP members are very generous and support many philanthropic efforts,” says Dr. Marciniuk. “Your personal pledge to this effort means improved care and a healthier outlook for patients and their families in the future.”

Visit the website for information on the benefits of giving, or contact Marilyn Lederer at (847) 498-8370 or mlederer@chestnet.org for more details on individual or group giving.
Continued from previous page

a document which outlines the enor-
mous worldwide burden of respira-
tory illness. The intent is to better inform, to raise awareness, and to as-
sist those who advocate for protecting and improving respiratory health. The document also highlights the many and varied threats to lung health and the stark realities of respira-
tory diseases throughout the world. Importantly, it outlines practical steps to make a positive difference in the respiratory health of the world. We believe it will be a useful and fre-
quently used tool in the fight against respiratory diseases and illness throughout the world. Final editing is currently underway on this docu-
ment, which we expect to be pub-
lished later this spring. We’ll be sure to let you know when it becomes available.

Royal Health-care Commission

The Commission recently completed its charge and submitted its report to the Board of Regents in March. I want to again personally thank those involved, and notably Commission Chair Dr. Scott Manaker, for their time and efforts.

The report covered a lot of ground but had a focus on College actions around health-care reform. It provided a comprehensive environmental scan of various activities and issues and developed a broad sense of priority issues affecting our members and our professions. The commission report importantly raises the practical issue of whether we can do things better to address the needs in this area. There may be an opportunity for innovative solutions and structures to meet both current and future needs—I think we can do better. We are giving considerable thought right now as to how best to provide the leadership our support and direc-
tion to our members and professions on this important subject.

CHEST World Congress 2014

Finally, the CHEST World Congress 2014, to be held in Madrid, Spain, on March 21-24, is certainly creating some excitement. This event will be a unique and innovative educational opportunity very different from other meetings and builds upon the proven expertise in clinical education of both the ACCP and SEPAR (Sociedad Espa-
ñola de Neumología y Cirugía Torácica - our colleagues from Spain).

The Scientific Program Committee, led by Co-Chairs Drs. Richard Irwin and Dr. Joan Soriano, and consisting of leading experts from around the world, is working hard to put together

the very best clinical educational offer-
ing. The committee is developing a sci-
entific programme that uses innovative educational methods to cover the full spectrum of clinical pulmo-

nary, critical care, and sleep medi-
cine. You can learn more about CHEST World Congress 2014 at chest.org.

You should know that this might be a ‘meeting’ for the entire family—it will be springtime and a great time of year to visit Madrid, Spain. Your fam-
ily (…especially if you promise to bring them along) might actually want you to register for this meeting! Now is the time to mark your calen-
dars, and plan to join colleagues from

around the world at the CHEST World Congress 2014.

So that is what the center of my desk looks like right now. As always, feel free to let me know what you think, or provide feedback on any activi-
ties of the College. Now I’m go-
ing to start working on some of

those other stacks....

VENDAVIS® (Iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration.

The STELIBNOS study established effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

VENTAVIS® (Iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve clinical improvement and lack of deterioration.

The STELIBNOS study established effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

VENTAVIS® (Iloprost) Inhalation Solution is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve clinical improvement and lack of deterioration.

The STELIBNOS study established effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).
Drug-resistant CRE: A new foe in our hospitals

BY GLENN S. TILLOTSON, PHD, FCCP

A recent health advisory issued by the CDC has highlighted the emergence of another clinically challenging, multidrug-resistant pathogen—CRE.

This collection of species has a mortality rate of over 40% and is clinically spreading across the United States with the highest number of cases being reported from northeas-
tern states. Moreover, the incidence of this disease has increased four-fold in the past decade, while CRE is now found in 27 states.

The first half of 2012 saw almost 200 hospi-

There are few clinical options to treat CRE infections, typically drugs include colistin, aminoglycosides, tigecycline, and fosfomycin, but none of these drugs is ideal, and each has ei-
ther toxicity or administration issues.

Combination therapies or pro-
longed infusions of carbapenems are
unproven; but in these situations, it may be the only option. Interestingly, there are several ß-lactamase in-
hibitors (BLIs) in clinical develop-
ment; some of which may provide some respite from CREs, including RPX7009 (Rempex Pharmaceuticals), avibactam (Forest Laboratories), and MK-7653 (Merck Laboratories). All are in phase 3 clinical trials for infec-
tions, such as hospital-acquired pne-
umonia and complicated urinary tract,
bleeding, and intra-abdominal in-
fections. These BLIs are being paired with both approved and development-
ald antibiotics, such as cefazidime, cefepime, imipenem, and mer-
openem. Most are being developed under the FDA’s new qualified infectious disease program (QIDP) program, which should enhance the regulatory ap-
proval process and encourage fur-
ther pharmaceutical investment.

The emergence of CRE is a serious threat to not only hospitals but to the community, where there is an increas-
ing number of patients with pre-
dispensing factors, such as advanced age, broad-spectrum antibiotic use, co-
morbidities, and medical interven-
tions. To reduce the impact of these strains, the CDC urges active case de-
tection and strict contact precautions for infected patients or those with evi-
dence of colonization appropriate an-
bacterial use in all settings, and clear communication about infections when patients transfer.

Learn more at: cdg.gov/haai organises/crc creflight.
BLOG: The world of medicine is flat and shrinking

BY DR. MARK J. ROSEN, FCCP
Director, ACCP Global Education and Strategic Development

Columbus gets the credit, but in 240 BC, Eratosthenes of Cyrene discovered that the earth was round. In 1990, the Hubbell telescope proved that the universe is expanding. However, in the 21st century, we know that the world is flat and the universe shrinking with a globalized economy, ease of travel, and technology. All aspects of modern life are changing, including medical science, practice, and education.

The term “global health” usually refers to researching and activity to improving health worldwide, integrating the perspectives of medical science, sociology, economics, and politics. It focuses on eliminating social and economic disparities that lead to problems in the undeveloped world, such as high rates of child and maternal mortality, along with so-called “diseases of poverty,” like malnutrition, malaria, cholera, and epidemic TB.

The affluent world has a different set of health problems, with global approaches to medical science and practice replacing old models of local expertise guiding patient care in local settings.

- Evidence-based medicine (EBM). Formal methodology is used to review and assess research in populations and to guide clinical decision-making for individual patients. Systematic review and grading of all available research is carried out, regardless of where the research is conducted.
- Clinical practice guidelines. These recommendations arise from the synthesis of the highest-quality evidence to inform practice. Where medical problems are similar in populations in different countries, it follows that medical practice should be similar, influenced by local resources and culture. Clinicians are obligated to keep up with guidelines related to their practice, regardless of where they practice.
- Globalized training. Physicians cross borders to train, including “international medical graduates” who come to the United States and who often return home.
- Academic and clinical outreach. Leading institutions, like Harvard University and Cleveland Clinic, collaborate in global educational and health system development.
- Medical tourism. Affluent patients from poor countries have always travelled to the United States and Europe for medical expertise and advanced technology. Patient travel to less-developed areas to receive expert care by Western-trained physicians in modern facilities at lower costs is increasingly popular.

- Teledicine. Patient monitoring and clinical expertise are available everywhere but still limited by high costs.

Technology is transforming medical education, with ongoing overhaul of content and delivery, framed by today’s approach to adult learning principles. In local and global contexts, paper textbooks and journals are being rendered obsolete because they are expensive to produce and distribute, usually outdated before they are published, not immediately accessible in daily patient care, and have no interactive features. With the disappearance of paper, the physical library is replaced with a virtual one that we carry in our pockets, that offers decision support, and allows interaction with peers. Likewise, the physical classroom is being replaced with online learning accessible any time and anywhere, and simulation technology is replacing the “see one, do one, teach one” approach to all aspects of practice.

Reprinted from Mark Rosen’s blog on April 14, 2013, at chestnet.org.

CHEST 2013: Inspire Chicago

Plan your stay with itineraries

There’s so much to do in Chicago—what makes it such a great city. ChooseChicago.com makes it easy for you to enjoy your Chicago experience with itineraries featured right on the website. Be sure to check out:

- Uniquely Chicago—a checklist of classic Chicago activities that demonstrate the breadth of activities in Chicago.
- Budget-Friendly Chicago—wonderful and affordable experiences that won’t require you to dig deep into your pockets.
- Family & Kids—endless options and kid-friendly suggestions to keep your family entertained.
- Architecture—a list of views and tours to highlight every angle of the city, above from a skyscraper or below from a walking tour.
- Food Lovers—award-winning fine dining establishments, family-friendly eats, and locals serving up everything from tasty cheap eats to avant-garde cuisine.
- Theatergoer—endless entertainment options with everything from blockbuster hits to edgy improv skits.

See all Chicago itineraries at ChooseChicago.com/plan-your-trip/itineraries.

CHEST 2013 takes place October 26-31, Recognized as the global authority in clinical chest medicine, it will feature a learning program in pulmonary, critical care, and sleep medicine. Watch for developing details at chestmeeting.chestnet.org.

Readiness assessments

BY RHONDA BUCKHOLTZ, CPC, CPMA, CPC-I, CGSC, COBGC, CPEDC, CENTC
AAPC Vice President of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) Education and Training

A crucial step in preparing for ICD-10 is clinical documentation improvement. Providers need help in getting their chart documentation ready to support the new level of specificity in ICD-10. If you randomly pull charts and assess the diagnosis documentation, you may get multiple diagnoses that cover multiple guideline issues in ICD-10. Struggling to cover too many things at once would make it difficult and frustrating to discuss with a provider. So where do you start?

First, run a report in your computer system and sort it by diagnosis code. Next, start with your top 10 codes, and run another report listing patients who had those diagnoses appended to them. Pull 10 to 20 charts with your top-used diagnosis code. Review the ICD-10-CM guidelines (if there are any) for the chapter in which the diagnosis is located. Then, review the notes for diagnosis ONLY. Look at the history and the assessment, and code it under ICD-10-CM. Put together a report based on the diagnosis: how many notes could be coded under ICD-10-CM? How many notes need more specific information to code? How many notes had to be coded to an unspecified code?

Take these findings to each provider and review them to show the specificity in ICD-10-CM and what is needed in the documentation to support the diagnosis. Go through all of the notes and answer all questions. Depending on how well the provider did on the assessment, you may either perform another assessment on the same diagnosis or move on to the next diagnosis on your “Top 10” list. The facility/office should have a target percentage for the assessments that all providers should meet. Reports should be kept on each assessment to show progression of the providers.

Once the assessments begin, they should continue until the implementation date of October 1, 2014. How often they occur depends on the number of providers you have, the number of different specialties, the type of specialties, and how the providers perform. When the code set begins official use, it will become part of the regular audit process.
Survey: How pulmonologists use biomarker testing

The American College of Chest Physicians (ACCP) recently partnered with Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on a survey exploring how pulmonologists from the ACCP incorporate biomarker testing into the care of patients with lung cancer; a similar survey was also conducted by Boehringer Ingelheim among pathologists. The survey results point to an increased role of these physicians in biomarker testing, as well as greater multidisciplinary collaboration. They also reveal an opportunity to improve how soon these tests are requested and to identify challenges with testing, including collecting a sufficient amount and quality of lung tissue.

Biomarker testing is critical in the diagnosis of lung cancer, as it helps physicians determine a patient’s specific type of cancer and inform a personalized treatment approach.

The results from the two surveys reflect responses and experiences of 100 ACCP pulmonologists and 250 pathologists practicing in the United States. The surveys were conducted online by Harris Interactive in November and December 2012.

Facing similar challenges

The two surveys revealed the potential need for consistent guidelines on the size and quality of tissue needed to perform biomarker testing. Both pulmonologists and pathologists said the biggest challenges with biomarker testing include not always acquiring a tissue sample that is sufficient in size (60% and 73%, respectively) or quality (31% and 39%, respectively). About half of pulmonologists surveyed (41%) do not believe they have enough information about the size of tissue needed.

Differing opinions

Survey responses highlighted a difference in opinions around the most appropriate tissue acquisition methods: 51% of pulmonologists believed endoscopy biopsy to be the method yielding the most appropriate balance between quantity and quality of tissue and risk to the patient; just 15% of pathologists agreed. In contrast, one-third of pulmonologists (33%) believed fine needle aspiration to be the best method, with only 10% of pathologists agreeing. Interestingly, 63% of pathologists and 44% of pulmonologists believe core biopsy to be the most appropriate method.

These findings suggest a need for greater guidance around the proper techniques to obtain tissue samples.

Figure 1

<table>
<thead>
<tr>
<th>Source: Boehringer Ingelheim</th>
<th>IMNG Medical Media</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biggest challenges regarding biomarker testing. Results taken from two surveys conducted online by Harris Interactive in late 2012, including 100 ACCP pulmonologists and 250 pathologists, respectively.</td>
<td></td>
</tr>
<tr>
<td>Continued on following page</td>
<td></td>
</tr>
</tbody>
</table>
Continued from previous page

of adequate size and quality at first biopsy. This is not only important for an accurate and rapid diagnosis, which can help inform treatment decisions, but also important for patients who would otherwise be subjected to additional risk by undergoing more than one invasive procedure to gather enough tissue samples for testing.

Opportunity for greater adoption of ‘reflex’ testing exists

Through reflex – or automatic – testing in advanced non-small cell lung cancer (NSCLC), tissue samples are tested for biomarkers immediately after diagnosis, with the goal of allowing oncologists to review the results before the patient’s first visit. The results from surveyed pulmonologists and pathologists suggest that they have started to embrace reflex testing, but there is potential to increase its use.

Specifically, nearly half (45%) of pulmonologists and one-third (33%) of pathologists implement reflex testing in their practice or local health-care community for patients with NSCLC (Fig 2).

Greater collaboration with the multidisciplinary team

In what should be good news for patients, the survey also showed that pulmonologists and pathologists are increasingly utilizing a multidisciplinary approach to care. In fact, pulmonologists and pathologists report having increased discussions with a multidisciplinary team over the past 5 years (65% and 57%, respectively), and most pulmonologists and pathologists report consulting with oncologists (85% and 92%, respectively) (Fig 3).

“The medical community is moving in a positive direction, but an opportunity exists for greater collaboration in incorporating biomarker testing into a patient’s care early on, with the goal of initiating an appropriate lung cancer treatment plan as soon as possible,” said Kevin Lokay, vice president and business unit head, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. “It is encouraging to see how a multidisciplinary approach to testing is becoming more common in the diagnosis and care of cancer patients.”

The surveys complement Boehringer Ingelheim’s Let’s Test initiative, which aims to educate health-care professionals about the important role they play in the diagnosis and treatment of NSCLC, and the critical role of biomarker testing.

If you would like to learn more about what ACCP is doing in the area of caring for patients with lung cancer, the new ACCP Lung Cancer Guidelines, 3rd edition, has been published as a supplement to CHEST in May 2013.

For more information, visit journal.publications.chestnet.org/.

Disclaimer: The data obtained from these surveys are self-reported and subjective; the ACCP was not directly involved in the writing of the survey questions, but rather participated by facilitating the collection of anonymous responses from its members.

Figure 2

<table>
<thead>
<tr>
<th>Pulmonologists (n = 100)</th>
<th>Pathologists (n = 250)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncologist</td>
<td>76%</td>
</tr>
<tr>
<td>Pathologist</td>
<td>46%</td>
</tr>
<tr>
<td>Me</td>
<td>43%</td>
</tr>
<tr>
<td>Pulmonologist</td>
<td>9%</td>
</tr>
<tr>
<td>Other</td>
<td>3%</td>
</tr>
<tr>
<td>Oncologist</td>
<td>74%</td>
</tr>
<tr>
<td>Pathologist</td>
<td>42%</td>
</tr>
<tr>
<td>Me</td>
<td>9%</td>
</tr>
<tr>
<td>Pulmonologist</td>
<td>3%</td>
</tr>
<tr>
<td>Other</td>
<td>3%</td>
</tr>
</tbody>
</table>

Source: Boehringer Ingelheim

IMNG Medical Media

Physicians who order biomarker tests for lung cancer patients. Results taken from two surveys conducted online by Harris Interactive in late 2012, including 100 ACCP pulmonologists and 250 pathologists, respectively.

Figure 3

<table>
<thead>
<tr>
<th>Oncologist</th>
<th>85%</th>
</tr>
</thead>
<tbody>
<tr>
<td>92%</td>
<td></td>
</tr>
<tr>
<td>Pathologist</td>
<td>69%</td>
</tr>
<tr>
<td>92%</td>
<td></td>
</tr>
<tr>
<td>Surgeon</td>
<td>21%</td>
</tr>
<tr>
<td>26%</td>
<td></td>
</tr>
<tr>
<td>Interventional cardiologist</td>
<td>13%</td>
</tr>
<tr>
<td>17%</td>
<td></td>
</tr>
<tr>
<td>Oncology nurse</td>
<td>3%</td>
</tr>
<tr>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>Primary care physician/general physician/family physician</td>
<td>1%</td>
</tr>
<tr>
<td>5%</td>
<td></td>
</tr>
<tr>
<td>Pulmonologist</td>
<td>29%</td>
</tr>
<tr>
<td>29%</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1%</td>
</tr>
<tr>
<td>4%</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>7%</td>
</tr>
</tbody>
</table>

Source: Boehringer Ingelheim

IMNG Medical Media

Consulting with various health-care professionals about biomarker testing. Results taken from two surveys conducted online by Harris Interactive in late 2012, including 100 ACCP pulmonologists and 250 pathologists, respectively.

Share knowledge through ACCP PREP® programs

In today’s health-care environment, our industry sales teams do not get a second chance to establish their credibility and knowledge. From the outset, they must be prepared and confident to truly engage with clinicians.

ACCP PREP is an intense clinical immersion program geared to help sales representatives understand the critical thinking that goes into the diagnosis and treatment of a disease state. Taught by clinicians and built by ACCP members, PREP gives sales teams the core clinical knowledge and behavioral insights they need to help health-care professionals achieve the best possible outcomes for patients.

ACCP members’ expertise is the advantage

ACCP PREP uses leading hospitals as the learning environment, so teams can experience the pressures and choices that clinicians face on a daily basis. Conducted at one site or multiple sites, after participants complete PREP, they’re better equipped to perform their daily duties and affect patient outcomes. They’re able to communicate more effectively with health-care teams and are more confident to begin the conversation. Most important, upon meeting all requirements, participants become certified by ACCP in a specific disease state for 3 years.

PREP’s value to ACCP’s mission

As a resource for evidence-based clinical practice guidelines and a world leader in forward-looking medical education, the ACCP is known for its ability to translate the latest data into clinical practice. Most recently, ACCP members helped develop and deliver a VTE PREP program. The ACCP would like to extend thanks to the following:

Curriculum faculty

Curriculum advisor: Lisa K. Moores MD, FCCP, Assistant Dean for Clinical Sciences, Professor of Medicine, The Uniformed Services University of the Health Sciences

Subject matter experts:

Jacob Collen, MD; Michael Gould, MD, FCCP; Christopher King, MD; David J. Rosenberg, MD; Aaron Tolley, MD.

On-site faculty:

Venkata Bandi, MD, FCCP; James Bartholomew, MD; Clayton T. Cowl, MD, MS, FCCP; Suhail Raoof, MD, FCCP

ACCP PREP programs help promote the education of our industry partners and help financially support the mission of the College. For more information or to become involved, contact Noreen Matthews at nnmathews@chestnet.org.
University of Cincinnati
Sleep Physician
The Division of Pulmonary, Critical Care and Sleep Medicine (PCCSM) at the University of Cincinnati and growing UC Health network seeks an ABMS BC/BE sleep medicine specialist to join our vibrant and growing 30 member group. Practice will include a busy sleep medicine outpatient service, interpretation of polysomnographies in the state of the art AASM-accredited UC Comprehensive Sleep Medicine Centers, and possibly training of fellows in an accredited joint Children’s Hospital/UC Sleep Medicine Fellowship. Candidates who are BC/BE in pulmonary and critical care medicine may also round on pulmonary outpatient and inpatient consult services, MICU services, and provide training for our fully accredited PCCM fellowship.

Please send curriculum vitae to:
Frank McCormack, MD
Division Director
Pulmonary, Critical Care & Sleep Medicine
University of Cincinnati
231 Albert Sabin Way
Cincinnati, OH 45267-0564
Telephone number (513) 558-4858
Email to Frank.mccormack@uc.edu

The University of Cincinnati is an Affirmative Action Equal Opportunity Employer.

Mount Nittany Health System is seeking BC/BE Pulmonary/Critical Care Specialists in State College, Pennsylvania, home of Penn State University.

1. Pulmonologist to join Mount Nittany Physician Group, Division of Pulmonology, which includes four BC Pulmonologists.
2. Critical Care/Intensivist for our developing program at Mount Nittany Medical Center State College, home to Penn State University, is a vibrant college town. It offers a diverse culture, a beautiful environment, excellent public and private schools, countless options for dining, theatre, sports and recreation, nightlife and more. This is all located within a safe, friendly community that makes the area perfect for raising a family. University Park Airport is located only five miles from town and State College offers easy access to Interstate 80.

Successful candidates will receive a highly competitive salary. Benefits include family health insurance policy, malpractice, CME allowance and a pension plan contribution.

Contact:
Lorelei Shaw
Director of Physician Recruitment
814-278-4866
ishaw@mountnittany.org
www.mountnittany.org

Watson Clinic LLP
Quality Healthcare for Every Generation
CRITICAL CARE/INTENSIVIST (between Tampa & Orlando, FL)
Watson Clinic, Lakeland’s premier, physician-led, multi-specialty group, is seeking an Intensivist to join 5 FT Intensivists to provide critical care services to medical, surgical, and cardiac patients at one 800-bed hospital.

- Fellowship training in Critical Care required
- Average day shift includes 10-12 patients
- Work schedule includes an average of thirteen 10-hr day shifts/mo & three 12-hr shifts/mo
- First year salary guarantee + signing bonus
- GREAT INCOME POTENTIAL
- Competitive benefits - professional liability insurance, relocation assistance, CME allowance, 401K

Lakeland/Central Florida is one of the fastest growing regions in the U.S. and Watson Clinic’s 200+ medical staff have distinguished themselves as healthcare leaders in our community of 500,000+. Residents and visitors enjoy a distinctive lifestyle with abundant recreation year-round, and NO STATE INCOME TAX!

WATSON CLINIC LLP
1600 Lakeland Hills Blvd. Lakeland, FL 33805
(800) 854-7786 Fax (866) 316-5876
e-mail: spaul@watsonclinic.com

U N I V E R S I T Y O F L O U I S V I L L E .
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
The University of Louisville invites applications for Chief of the Division, which includes 15 faculty and 10 fellows that staff specialized programs in cystic fibrosis, interstitial lung disease, pulmonary hypertension, interventional pulmonology, lung transplantation, sleep medicine, and critical care.

The clinical enterprise spans the University Hospital, VA Hospital, and Jewish Hospital in downtown Louisville. Research includes clinical trials as well as basic research in oxidant stress, neural control, and lung injury and repair, rejection after transplantation, and cancer.

The successful candidate will have support to recruit additional faculty and will provide leadership for the Pulmonary/CCM, Interventional, and Sleep Fellowship Training Programs, research, and clinical missions. Candidates must be board certified in Internal Medicine and Pulmonary and BC/BE in Critical Care. The tenured, academic appointment, and compensation will be commensurate with the successful candidate's level of development.

Interested applicants should send CV to Jesse Roman, M.D., Chairman
Department of Medicine, University of Louisville
530 S. Jackson Street, Louisville, KY 40292
j.roman@louisville.edu

The University of Louisville is a non-discriminatory, affirmative action employer and encourages women and minorities to apply.

University of Cincinnati
Sleep Physician

The Division of Pulmonary, Critical Care and Sleep Medicine (PCCSM) at the University of Cincinnati and growing UC Health network seeks an ABMS BC/BE sleep medicine specialist to join our vibrant and growing 30 member group. Practice will include a busy sleep medicine outpatient service, interpretation of polysomnographies in the state of the art AASM-accredited UC Comprehensive Sleep Medicine Centers, and possibly training of fellows in an accredited joint Children’s Hospital/UC Sleep Medicine Fellowship. Candidates who are BC/BE in pulmonary and critical care medicine may also round on pulmonary outpatient and inpatient consult services, MICU services, and provide training for our fully accredited PCCM fellowship.

Please send curriculum vitae to:
Frank McCormack, MD
Division Director
Pulmonary, Critical Care & Sleep Medicine
University of Cincinnati
231 Albert Sabin Way
Cincinnati, OH 45267-0564
Telephone number (513) 558-4858
Email to Frank.mccormack@uc.edu

The University of Cincinnati is an Affirmative Action Equal Opportunity Employer.

Mount Nittany Health System is seeking BC/BE Pulmonary/Critical Care Specialists in State College, Pennsylvania, home of Penn State University.

1. Pulmonologist to join Mount Nittany Physician Group, Division of Pulmonology, which includes four BC Pulmonologists.
2. Critical Care/Intensivist for our developing program at Mount Nittany Medical Center State College, home to Penn State University, is a vibrant college town. It offers a diverse culture, a beautiful environment, excellent public and private schools, countless options for dining, theatre, sports and recreation, nightlife and more. This is all located within a safe, friendly community that makes the area perfect for raising a family. University Park Airport is located only five miles from town and State College offers easy access to Interstate 80.

Successful candidates will receive a highly competitive salary. Benefits include family health insurance policy, malpractice, CME allowance and a pension plan contribution.

Contact:
Lorelei Shaw
Director of Physician Recruitment
814-278-4866
ishaw@mountnittany.org
www.mountnittany.org

Watson Clinic LLP
Quality Healthcare for Every Generation
CRITICAL CARE/INTENSIVIST (between Tampa & Orlando, FL)
Watson Clinic, Lakeland’s premier, physician-led, multi-specialty group, is seeking an Intensivist to join 5 FT Intensivists to provide critical care services to medical, surgical, and cardiac patients at one 800-bed hospital.

- Fellowship training in Critical Care required
- Average day shift includes 10-12 patients
- Work schedule includes an average of thirteen 10-hr day shifts/mo & three 12-hr shifts/mo
- First year salary guarantee + signing bonus
- GREAT INCOME POTENTIAL
- Competitive benefits - professional liability insurance, relocation assistance, CME allowance, 401K

Lakeland/Central Florida is one of the fastest growing regions in the U.S. and Watson Clinic’s 200+ medical staff have distinguished themselves as healthcare leaders in our community of 500,000+. Residents and visitors enjoy a distinctive lifestyle with abundant recreation year-round, and NO STATE INCOME TAX!

WATSON CLINIC LLP
1600 Lakeland Hills Blvd. Lakeland, FL 33805
(800) 854-7786 Fax (866) 316-5876
e-mail: spaul@watsonclinic.com
Bozeman, Montana
Living the Dream

Bozeman Deaconess is hiring a Pulmonary/CC physician so start living the dream today! This is an employed inpatient/outpatient opportunity with Bozeman Deaconess Hospital which has an 8 bed ICU and call is 1:4 with a 4 day week work allowing time to enjoy the six mountain ranges surrounding the community, major rivers, 5 golf courses, world class skiing, 284 mountain trails, Montana State University, gateway to Yellowstone National Park it is no wonder Bozeman, Montana appeared as No. 2 on the top 10 list for bizjournals.com’s list of American “dream towns.”

Contact: Selina Irvy, Physician Recruiter BDH-sirby@bdh-boz.com (P) 406-556-5186, (F) 406-556-5240. Apply online www.bozemandeaconess.org/careers

Asheville, NC
Pulmonary/Critical Care Medicine Physician needed for combination inpatient/outpatient practice opportunity (Sleep Medicine optional) w/call rotation. Inpatient-only/Outpatient-only option. Convenient location adjacent to UNC Health Care affiliated Pardee Hospital. Beautiful Hendersonville, Western NC (near Asheville).

No Visa Sponsorship.

Contact: Lilly Bonetti, FASPR Pardee Hospital (828) 694-8342 lilly.bonetti@pardeehospital.org www.pardeehospital.org

Louisville, KY
8 person well established single specialty Pulmonology group in Louisville, KY seeking pulm/cc physician. Competitive salary and partnership track. Opportunity to practice inpatient and outpatient pulmonary & critical care. Sleep medicine available but not a must. Please send CV to: kvanderpool@kpacdocs.com

Los Angeles, CA
Established Pulmonary, Critical Care, Sleep Medicine and Hospitalist Practice located in downtown Los Angeles has an opening for a Board Certified or Board Eligible Pulmonary/ Critical Care/Sleep physician. Salaried position with opportunity to develop personal interests. Email: nbovitz@yahoo.com

MD:
MEDICAL DIRECTOR
PULMONOLOGY/ICU
TORRANCE, CA

Torrance Memorial Medical Center, located in a beautiful coastal community in Los Angeles County, CA, is seeking two Pulmonologists and Critical Care Medicine BC physicians. The selected physicians will serve as co-medical directors in the ICU and Pulmonary Department at this 420 bed general acute hospital with 30 intensive care beds. Responsibilities include in-house critical care, pulmonary consultations, and medical directorships, as well as providing office-based care on a part time basis.

Slated to open a new main tower in early 2015, Torrance Memorial has been deemed a “Hospital of Tomorrow.” The new tower will be home to the ICU and will feature the latest medical technologies, patient amenities and diagnostic capabilities.

It is designed to serve the projected future needs of patients, physicians, employees, and visitors.

EXCEPTIONAL HEALTHCARE
Here Now. Advancing Daily.
For details, contact: Jennifer Westford, Recruiter
Phone: 412-364-8200 - Email: jwestford@corazoninc.com

PULMONOLOGIST

METRO SOUTH CAROLINA: Hospital employed joining 10 physician Pul/CC group two hours to Atlanta/Charlotte associated with 420 bed health system. 1-3 call. SEATTLE AREA: Hospital employed adding two with existing Pul/cc employed adding two with existing Pul/cc associate with 420 bed health system. 1-3 call. SEATTLE AREA: Hospital employed adding two with existing Pul/cc physician 45 minutes to Seattle associated with new 137 bed hospital on Puget Sound. 1-3 call. Excellent salary, bonus and benefits. DONOHUE AND ASSOCIATES. 800-831-5475
EM: donohueandassoc@aol.com

PROFESSIONAL OPPORTUNITIES

KLASSIFIEDS
Also available at www.MedJobNetwork.com

KEEP UP-TO-DATE
Watch our Classified Notices for Postgraduate Course information.

Living Well Means Breathing Well.

ONE Breath
Make The Most Of It.

Join the Online Community
OneBreath.org

Follow the ACCP
facebook.com/acpcchest
twitter.com/acpcchest

FIND YOUR NEXT JOB AT
MEDJOBNETWORK.com
The first mobile job board for Physicians, NPs, and PAs
MEDJOBNETWORK.com on the go from your smartphone or tablet.
Advanced Search Capabilities to search for jobs by specialty, job title, geographic location, employing entity, and more.

Disclaimer Chest Physician assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.
3rd Edition of the ACCP Lung Cancer Guidelines published

BY SANDRA ZELMAN LEWIS, PHD; REBECCA DIEKEMPER, MPH; AND VICKI TEBESCHI

The Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, was published as a supplement to the May issue of CHEST.

The print supplement includes the Executive Summary, which features all the recommendations, the Introduction, and Methodology chapters. The online version provides the complete supplement, with all full-text articles, supplemental tables, podcasts, and more. The guidelines can be viewed on any smartphone using the mobile-enhanced site or on the CHEST journal app for iOS devices.

The ACCP lung cancer guidelines, first published in 2003, have become one of the most comprehensive and respected guidelines in the lung cancer community. The 2nd edition had more than 300,000 accesses from the journal’s website and, even 5 years later, more than 163,000 views were chronicled in this past year alone through the National Guideline Clearinghouse.

Readers will note many advances in the updated guidelines. This 3rd edition of the guidelines (LC III) heralds a significant advance in the science of evidence-based medicine. Innovative procedural and methodological advances have resulted in many changes in the recommendations, both clinically and in terms of the strength of the recommendations. Some of the strong recommendations in the 2nd edition have been downgraded to moderate or weaker levels mainly because the newer more rigorous assessments of the quality of the evidence have led to lower confidence in the estimates of effect.

The ACCP Guidelines Oversight Committee conducted meticulous reviews of nominees’ conflicts of interest. The final manuscripts underwent a thorough and precise review process, resulting in recommendations that readers can trust.

Specific changes to these guidelines include:

- The screening recommendations in LC III are very specific and more inclusive of other modalities.
- These follow a 2012 multisociety guideline on screening in which the ACCP was a leading partner.

An article on tobacco cessation for lung cancer patients breaks new ground in this publication. Patients with lung cancer who smoke should be treated by their physicians using pharmacotherapeutic and behavioral approaches to help end their dependence on tobacco.

The newest staging system is demonstrated, and methods for staging lung cancer in patients are explored in detail. As with past editions, the treatment articles are divided by stage of illness, small cell lung cancer, and special treatment issues. But the comprehensive and systematic evidence reviews have yielded the newest evidence on treatments for these patient populations.

This edition includes a comprehensive review with recommendations for managing the symptoms experienced by patients with lung cancer even before they approach the end of life.

Complementary and integrative oncology treatments are explored and held to the same evidence-based standards. A number of randomized controlled trials, meta-analyses, and systematic reviews were revealed, and many recommendations address the benefits of integration of approaches from pulmonary rehabilitation to acupuncture and massage and more.

Clinical resources, including slide sets for presentations to lay and professional audiences, and educational programs will be made available over the next several months and during CHEST 2013 in Chicago in October. Please watch for announcements in your inbox and on www.chestnet.org.

The ACCP is working hard to produce the very best evidence-based clinical guidelines in chest medicine. You can access the LC III guidelines at journal.publications.chestnet.org.

For more information, please contact Sandra Zelman Lewis, PhD, slewis@chestnet.org.

References
Thoracic Oncology

CHEST sessions, e-Community, and projects.

CHEST 2013 will provide a spectrum of educational forums and topics related to thoracic oncology. The general sessions and highlights will address areas relevant to the practicing clinician, trainee, and thoracic oncology specialist. The ACCP Lung Cancer Guidelines, 3rd ed (LCCIII), will be highlighted throughout the meeting. There are plans to share some sessions via video teleconferencing with the World Conference on Lung Cancer taking place in Sydney, Australia, at the same time. Other sessions focusing on lung cancer screening, lung nodule evaluation, staging, chest imaging, and appropriate tissue acquisition have been planned. In addition, there is a lung cancer track that follows the full morning of the meeting where one-half day will be spent focused on our specialty. Our NetWork Featured Lecture is a great opportunity to meet others with shared interests and find ways to be engaged in the NetWork’s activities.

The College has provided us with a venue to improve communication within and between the NetWorks and our membership. The ACCP e-Community provides relevant resources for those interested and a forum for discussions about new or controversial topics in thoracic oncology. Look forward to enhanced links to helpful material and a series of focused discussion topics. We encourage you to visit and contribute to this site.

Our NetWork and our membership are involved in projects of various scope and at different stages of development. Many NetWork members have dedicated a great deal of time to the production of the LCIII guidelines. A project aiming to develop Quality Indicators for the Evaluation and Staging of Lung Cancer is nearing completion, and a project aiming to provide guidance on the ideal means of tissue acquisition and processing is being discussed. Overall, it is an exciting time, with many developments in thoracic oncology leading to opportunities for education and research. Our NetWork welcomes your ideas and participation in these efforts.

Dr. Peter Mazzone, FCCP
NetWork Chair

Robert G. Loudon, MBChB, FCCP, died January 1, 2013. He was the Pulmonary and Critical Care Division Chief from 1971 to 1992 at the University of Cincinnati Medical Center.

During his 21 years as Division Chief, he helped expand the division with the introduction of flexible bronchoscopy, critical care, and sleep medicine. Dr. Loudon moved from studies of cough as a method to transmit tuberculosis to studies of lung and cough sounds. With Raymond Murphy, MD, FCCP, he founded the International Lung Sounds Association. This multinational group helped codify lung sound terminology.

As a Fellow of the ACCP, Dr. Loudon participated in the International Affairs Committee; as Chair of the Credentials Committee; and as a Regent at Large.

He is survived by his wife, Dorothy, and three daughters, Elizabeth, Sarah, and Kate.

Interventional Chest/Diagnostic Procedures

New codes for percutaneous pleural procedures

Pleural procedures have long been part of the routine practice of pulmonary and critical care providers. The widespread use of imaging guidance, primarily ultrasound, is now prevalent. In addition, the use of various pleural catheters has extended beyond interventional radiology. Traditional tube thoracostomy has been largely replaced by pigtail or indwelling tunneled pleural catheters.

Pleural interventions can be done in an ambulatory setting, at the bedside, or in a procedure/operative setting. Ultrasound and/or fluoroscopy is used to guide the procedure to minimize risk and to access small or loculated collections.

For thoracentesis, there is no longer a distinction between needle-only (diagnostic, 32421 deleted) and catheter-based drainage (therapeutic, 32422 deleted). These are now equivalent and coded without (32554) or with (32555) imaging guidance. Code 76942 is no longer reported for imaging guidance during thoracentesis. Report 32405 for percutaneous biopsy of the lung or mediastinum (32420 has been deleted).

For small-bore percutaneous pleural catheters (without cuff), there are two new codes with similar distinction as thoracentesis; without (32556) and with (32557) imaging guidance. These are used when a catheter is placed into the pleural space, without dissection. Traditional open large-bore tube thoracostomy is still coded as 32551; however, references to hemothorax and empyema have been removed.

Radiology codes (75989, 76942, 77002, 77012, 77021) are not to be used with 32554 or 32556, and imaging is bundled into both 32555 and 32557. Placement (32550) and removal (32552) of indwelling tunneled pleural catheters, pleurodesis (32560), and intrapleural fibrinolysis (32561, 32562) codes remain unchanged.

Dr. Mohit Chawla, FCCP
Steering Committee Member; Dr. Kevin L. Kovitz, FCCP; and Ms. Kim French, MHSA, CAPPM

This Month in CHEST: Editor’s Picks

BY DR. RICHARD S. IRWIN, MASTER FCCP
CHEST Editor in Chief

EDITORIAL


COMMENTS

US Food and Drug Administration-Managed Trials of Long-Acting β-Agonists Safety in Asthma: Will We Know the Answer? By Drs. S. Suissa and A. Ariel.

ORIGINAL RESEARCH

Efficacy of Single-Dose Antibiotic Against Early-Onset Pneumonia in Comatose Patients Who Are Ventilated. By Dr. J. Valles et al.

Incidence of Severe Asthmatic Reactions After Challenge Exposure to Occupational Agents. By Dr. O. Vandenberg et al.

Obstructive Sleep Apnea in Patients With Typical Atrial Flutter: Prevalence and Impact on Arrhythmia Control Outcome. By Dr. V. Bazzan et al.
Why is this patient short of breath?

A simple, six-minute in-office test can help you find out with no capital risk to your practice.

In just six minutes Shape® can help drill down to the root cause of exertional dyspnea – right in the clinic. Shape is simple, objective and intuitive. With our pay-per-procedure plan there's no cost for the device. Shape elevates cardiopulmonary exercise testing to a new level.

Learn more by calling 1-888-SHAPE98 (888-742-7398) or by visiting www.shapemedsystems.com.